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Executive summary  
• HIV and AIDS have caused a global catastrophe. Around 38 million people 
are infected, and the human, social and economic costs are huge. The 
pandemic has spawned a global response and an international pool of expertise 
is now emerging. However, the funding available to take advantage of 
increasing knowledge and growing initiatives is inadequate, and private 
individuals can play a helpful role on many levels.  
• The vicious circle of infection and poverty increases the spread and 
worsens the effects of HIV/AIDS. The epidemic must be tackled on multiple 
fronts.  
o Prevention works best when its messages are conveyed in tandem 
with care and treatment programmes.  
o As those affected (be they infected adults or orphaned children) sink 
into greater poverty, so their risk of contracting or transmitting the virus 
increases. It is vital to address poverty and vulnerability in order to 
protect those at risk. 
o The epidemic is increasingly stretching medical infrastructures, which 
could deliver care and treatment to those infected with HIV – health 
management systems must be improved to maintain and expand 
medical infrastructure, but not at the expense of other life-threatening 
diseases. 
o National efforts involving local governments, local communities and 
those directly affected should be encouraged and supported while 
duplication by outsiders avoided – collaboration among donors and 
service providers is essential to the success of responses. 
o International and regional efforts to find solutions (treatment trials, the 
quest for effective protection measures) should be supported, as well 
as national efforts. 
• It is difficult, but not impossible, to fund and implement projects in Africa. There 
are a number of approaches available to donors outside the region: either 
support local NGOs via donors and agencies already on the ground, or fund 
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Introduction 
The purpose of this report 
This report provides detailed contextual information and analysis that is required to 
understand HIV/AIDS on a regional and global scale. It is aimed at donors who wish to fund 
projects to help those affected by HIV/AIDS in Africa. The report also examines the ensuing 
social needs, types of response in operation, and the results generated by such 
interventions. 
 
The report is addressed to private individuals, companies, funders, and grant-makers. While 
it aims to help all in this spectrum, it should be recognised that parts of the report have been 
written for the benefit of newcomers to the subject.  
 
Funding this complex and rapidly changing issue, at considerable geographical distance 
from the donor, is far from straightforward. Few foundations or private individuals are in a 
position to dedicate in-country resources to support their grant-making.  
 
This overview puts the case for combating the effects of the pandemic, analyses the delivery 
mechanisms, and advises how donors can target their resources most effectively. It is 
designed to be read in conjunction with NPC’s other reports: 
• Out of the shadows: HIV/AIDS in Burundi, Democratic Republic of Congo and Rwanda; 
• Rhetoric to Action: HIV/AIDS in South Africa. 
 
Experienced funders can use this report as a starting point for debate and further research. 
This overview does not contain all the answers – but it may help to steer organisations into 
interesting directions, particularly at the global and regional level. 
 
The content of this report 
The report is based on research carried out through extensive meetings with organisations, 
researchers, policy makers, analyses of charity accounts and activities, and reading of 
research materials. NPC’s visits to Central Africa form an integral part of the research. NPC 
visited many projects in the field and held meetings with experts, project workers and 
beneficiaries. In addition, NPC met with some of the major international agencies and 
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Glossary 
AIDS: Acquired Immunodeficiency Syndrome 
ARVs: Antiretroviral drugs. A Q&A about ARVs is available separately on the NPC website. 
ART: Antiretroviral treatment or therapy. See above. 
AZT: Azidothymidine (chemical name), Zidovudine (generic name), Retrovir ® (brand name) 
– drug used as part of triple-therapy antiretroviral treatment. 
CBO: Community based organisation 
CD4+ T-lymphocyte: A type of white blood cell which is critical to the immune system. The 
normal count for a health person is 500-1600. A count below 200 is considered highly 
dangerous and is often the trigger for ARV treatment. 
DRC: Democratic Republic of Congo (the French acronym is RDC) 
Discordant: Refers to a sexual partnership where one party is HIV positive and the other 
HIV negative. 
Donors: Persons or organisations choosing to make a financial contribution to a project, 
charity or programme – covers a wide range from grant-makers, bi-lateral country to country 
donors, to companies and private individuals. 
FBO: Faith based organisation 
HIV: Human Immunodeficiency Virus 
HIV positive: A positive diagnosis occurs if antibodies for HIV (not HIV itself) are detected. 
HIV negative indicates that no antibodies have been detected and implies a lack of infection. 
HAART: Highly Active Antiretroviral Treatment or therapy, closely monitored treatment with 
triple-therapy ARVs. This may also be referred to as ART.  
ICHC: Integrated community based home care 
Microbicide: Substance that can substantially reduce transmission of sexually transmitted 
infections (STIs) when applied either in the vagina or rectum. 
Morbidity: Incidence of sickness/disease, diseased/sick condition. 
Mortality: Death rate, death. 
MTCT: Mother to Child Transmission of HIV  
Nevirapine: Nevirapine (trade name Viramune) is one of a class of drugs called non-
nucleoside reverse transcriptase inhibitors (NNRTIs) used in the treatment of HIV/AIDS. 
NGO: Non-governmental organisation 
Opportunistic Infections: Diseases that attack, and may eventually kill someone whose 
immune system has been weakened by AIDS. 
Orphan: International convention is that an orphaned child may have lost either one or both 
parents.1 
Pip: Per infection prevented, a short-hand term coined in the outcome section of this report. 
PMTCT: Prevention of mother to child transmission of HIV, using ARVs to reduce the risk. 
STI or STD: Sexually transmitted infection or disease 
TB:  Tuberculosis 
US$: GPB exchange rate: US$1.78:£1 used throughout (rate of conversion as of 
September 15, 2004 using www.xe.com universal currency converter). 
Viral load: A measure of the density of HIV in body fluids. 
VCT: Voluntary Counselling and Testing 
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Acronyms of NGOs, national and international organisations 
 
AMREF  African Medical Research and Education Foundation 
BTC Belgian Technical Cooperation 
DfID  Department for International Development, part of UK government responsible 
for overseas aid and development. 
GTZ Deutsche Gesellschaft für Technische Zusammenarbeit or German Technical 
Cooperation 
ICRC International Committee of the Red Cross 
MSF  Médecins Sans Frontières (Doctors without Borders), a leading medical NGO 
TAC Treatment Action Campaign, lobbies for universal ARVs in South Africa. 
UNAIDS Joint United Nationals Programme on HIV/AIDS 
UNDP United Nations Development Programme 
UNFPA United Nations Population Fund 
UNHCR United Nations High Commissioner for Refugees 
UNICEF United Nations Children’s Fund 
WHO World Health Organisation 
WTO  World Trade Organisation 
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Section 1: HIV/AIDS epidemic – a global and 
regional perspective 
 
HIV and AIDS have caused a global catastrophe. Around 38 million people are 
infected, and the human, social and economic costs are huge. The pandemic has 
spawned a global response and an international pool of expertise is now emerging.  
 
This section starts by explaining the basic facts of HIV/AIDS from a clinical, social 
and epidemiological perspective. It then explores the international response to the 
crisis and highlights its financial deficiencies. The report then examines the measures 
available to those trying to break the vicious circle of HIV/AIDS and poverty, and 
looks at data available from studies in a wide geographical area, indicating efficacy or 
otherwise.  
 
What is HIV/AIDS? 
HIV: The Human Immunodeficiency Virus destroys the immune system itself. 
However, an individual can live a normal healthy life while HIV positive, until the 
destruction is so far advanced that the immune system can no longer fight off 
infections. There are many different strains of the virus because it replicates and 
mutates at high rates. 
 
AIDS: Acquired Immunodeficiency Syndrome is diagnosed when a person’s 
immune system has been seriously damaged by HIV and the organism is 
attacked by ‘opportunistic infections’, such as tuberculosis (TB) or common flu, 
against which it no longer has a sufficient defence. At this point, which happens 
on average ten years after infection with HIV, the individual becomes extremely 
sick and antiretroviral treatment is needed. In places where people’s immunity is 
depressed and exposure to disease is high, the development of AIDS is much 
faster for those who are HIV positive. 
 
Of the 38 million people infected with the virus, 25 million live in sub-Saharan Africa 
(equating to a prevalence of 7.5%).Of the three million people dying of AIDS each year, 2.2 
million live in sub-Saharan Africa. As a global killer, TB comes a close second at two million 
per annum. HIV and TB co-infection rates are high: in Zambia up to 70% of TB patients are 
Figure 1: Global view of HIV infection as of end 2003
Source: UNAIDS 2 : 38 million (range 35-42 million) living with HIV 
 
HIV positive, conversely up to 50% of HIV positive patients develop TB. Without 
antiretroviral drug treatment, TB mortality in HIV positive patients is 100%. In addition, the 
Globally 38 million 
people are infected 
with HIV: three 
million people die of 
AIDS each year. 
25 million of these 
live in sub-Saharan 
Africa, with 2.2 
million dying. 
 
TB and HIV go hand 
in hand - without 
ARV drug treatment, 
TB mortality in HIV 
positive patients is 
100%.  
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presence of TB puts the families of those infected at risk of contracting it. The data shown in 
the map in Figure 1 do not distinguish between genders, but there is a trend for increasing 
numbers of women becoming infected; the male population’s infection incidence is not rising 
at the same rate. This is because women are more vulnerable to infection than men. 
 
There are other significant causes of death on the continent and it is important not to lose 
sight of these when considering the HIV/AIDS epidemic. World Health Organisation (WHO) 
data indicate that AIDS accounts for 19% of deaths in Africa, while malaria is responsible for 
10% of deaths, maternal and perinatal conditions for 7.4%, cardiovascular disease for 10%, 
TB and respiratory infections for 13%, and diarrhoea and childhood diseases for 13.6%.   
Some of these diseases may be HIV-related. Cancers are also present on the continent. 
 
Although many people with HIV can live healthily for a reasonable period, when AIDS 
reaches its final stages, the symptoms are unpleasant: chronic diarrhoea, wasting, flaky 
skin, and sores from various infections and herpes; swallowing and digestion are often 
difficult because of infections. Candida (thrush) in the mouth, gut and genital areas can also 
be present. If TB occurs, this will contribute to the decline in health. 
 
 
Effect of HIV/AIDS  
HIV prevalence data are leading indicators of the scale that the AIDS pandemic will reach in 
coming years. There is a time lag, which may be as long as a decade, between persons 
being infected with HIV and developing full-blown AIDS.  
 
A dramatic indicator of the impact of HIV/AIDS is its effect on life expectancy. To take an 
example, life expectancy in Botswana peaked in the late 1980s at around 62. By 2002 it had 
plummeted to 37. A portion of these deaths would have occurred anyway – in the absence 
of HIV/AIDS, TB results in death in more than 60% of cases if left untreated although the 
number of TB cases rises where HIV is present in a community. However, the vast majority 
of deaths were additional mortalities resulting from immune systems weakened by HIV, 
which robs victims of the ability to fight life threatening infections. 
 









ordinary adults  









who are HIV -ve
 
The HIV/AIDS pandemic is creating a vicious circle of infection and poverty: infection 
increases poverty in families and communities, poverty increases the vulnerability of those 
affected, and so on. One of the features of the HIV/AIDS pandemic is the children left as 
orphans; many may be HIV positive themselves. In 2003, 14 million children under the age 
of 15 had lost one or both parents to AIDS. This number is expected to exceed 25 million by 
2010; eleven million are living in sub-Saharan Africa.  
 
A recent World Bank report warns that HIV/AIDS causes significant long-term economic 
damage. AIDS destroys human capital directly by killing young adults and it weakens human 
Women are more 
vulnerable to 






at 62. It is now 37. 
Globally 14 million 
children have lost 
one or both parents 
to AIDS. 11 million 
live in Africa. By 
2010 the global 
figure will rise to 25 
million. 
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capital formation because orphans are deprived of love and guidance and spend much less 
time in school. The poor education of children today translates into low adult productivity a 
generation later. 
 
If orphaned children are not given adequate care and education, there will be increasing 
inequality among the next generation of adults and the families they form. With such a sharp 
increase in adult mortality there may not be enough people to adopt or foster orphans, 
thereby shifting the onus onto the government. Governments, however, will be less able to 
finance orphan care because tax bases are weakened when adults are killed by AIDS. The 
World Bank report stresses: “Keeping infected people alive and well, especially parents, so 
they can continue to live productive lives and take care of the next generation, is not only the 
compassionate thing to do, but is also vital for a country’s long-term economic future.” 
 
Women and girls are probably feeling the effects most. Not only are they more vulnerable to 




Obtaining reliable and consistent data on infection rates is difficult and the quality of data 
and method of collection varies enormously between countries. The key indicator used to 
measure the epidemic is prevalence, ie, the number of people infected with HIV as a 
proportion of the population. 
 
However, prevalence as a measurement tool is flawed: death rates affect prevalence trends 
and may mask the underlying direction of an epidemic. For example, if an epidemic has 
reached a peak point in mortality, prevalence rates will drop as people die, even though the 
incidence of infection may still be as high as ever. Incidence – the measurement of 
additional cases of infection per unit of time – is a much better indicator, but is more difficult 
to measure, and few sentinel sites are actually attempting to do so. 
 
Prevalence statistics can be more useful if information is collected about specific age 
groups. A reduction in prevalence in, for example, the 15-19 age range – where those 
infected are not yet dying – would indicate that the incidence of HIV is falling and progress is 
being made in combating the spread of infection.  
 
There are various ways in which data can be collected, ranging from general population 
surveys (such as one carried out in South Africa) to statistics collected from ante-natal 
clinics. Each method has its pros and cons. General population surveys are difficult to carry 
out and expensive, and may miss crucial groups. Ante-natal clinic data are a good, regular 
source of information but only relate to women of child-bearing age and do not show what is 
happening to men. However, as young women are one of the groups most at risk, such data 
are interesting. Some countries have a paucity of sentinel sites (eg, the Democratic Republic 
of Congo) and wide regional variations hamper coherent analysis of epidemiological trends. 
This is frustrating for those trying to determine prevention strategies. 
 
However, the prevalence data are valuable because they can be used to estimate the 
ranges of need (especially for treatment and care) and the number of future orphans. 
 
 
Why has the epidemic spread widely in sub-Saharan Africa?  
It is important to stress that there are significant regional differences in the epidemic in terms 
of prevalence and incidence rates and reasons why transmission occurs. Southern Africa 
has been severely affected, as has East Africa. North Africa is almost unscathed, and parts 




Over 90% of HIV infected adults in sub-Saharan Africa acquired HIV through heterosexual 
intercourse. It may be helpful, therefore, to explain some of the factors that have a bearing 
on sexual transmission: 
 
• Poor health, including malnutrition, weakens the body’s immune defence against 
the virus.  Transmission of the virus from an HIV positive partner to an HIV negative 
partner is not automatic, particularly between healthy individuals. The virus is less 
likely to have an opportunity to invade cells and membranes that are well 
nourished, healthy and not weakened by repeated infection.3 
Southern Africa and 
East Africa are 
severely affected. 
North Africa is 
almost unscathed, 
and parts of West 
and Central Africa 




accounts for 90% of 
adult HIV infections 
in sub-Saharan 
Africa. 
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• Sexually transmitted infections are the perfect vector for HIV. Ulcers, inflammation 
and rashes provide HIV with easy entry points during intercourse. In addition, 
infections reduce natural immunity to the virus. 
• HIV viral load of the infected person is particularly high in the first three months 
after initial contraction of the virus and high levels of viral load increase the risk of 
transmission. The viral load then reduces for a number of years before increasing 
as the patient develops AIDS.  
• Male circumcision may possibly be one of the factors explaining the difference in 
HIV rates between Western Africa, where circumcision is routinely practised and 
HIV prevalence is lower, and Southern Africa, where it is uncommon. Researchers 
are still exploring the reasons for this. 
• Sexual practices (eg, use of vaginal drying agents) and/or coercion might result in 
abrasion or laceration of membranes which provide entry points for the virus, and 
consequently increase likelihood of transmission.  
 
Box 1: Sex and the spread of the epidemic 
“We’re just beginning to understand that where AIDS is concerned, gender 
inequality is lethal. It requires a campaign, across the continent and the world, to 
enshrine gender equality in the family, in the laws, in the institutions and in the 
apparatus of the State.” 4  
 
In order to implement effective prevention strategies, reduce stigma and enable 
people to seek treatment, or to protect themselves against the virus, one must 
understand the nature of sexuality in Africa, its intimate connection with self-
esteem and the taboos surrounding its discussion. 
 
In places where men have few opportunities for material satisfaction or other 
indicators of success, sexual encounters are an important way of demonstrating 
masculinity. At the same time, women are expected to submit to men (without 
being obviously promiscuous) 5 and enjoy few rights of refusal, particularly if self-
esteem is low.  
 
The ‘sugar-daddy’ syndrome is clearly visible in some HIV prevalence statistics, 
and highlights the vulnerability of young women. This usually involves an older, 
sexually experienced man courting a much younger ‘girlfriend’ with gifts, 
groceries or cash, which she receives in return for sex. Where poverty is acute, 
sex is one of the few routes to a square meal.6 The older man, with a sexual 
history, is likely to be infected and may pass the virus to the younger girl. AIDS 
develops slowly: the risk of death from a disease that will manifest itself in the 
distant future seems less of a hazard than the immediate need for food. The 
infected participants may continue to look healthy and attractive, and move on to 
other partners.  
 
Marriage represents a particular hazard for young girls, as condom use or 
abstention is unlikely to be negotiable and girls generally cede economic and 
personal power to their partners. Even if one partner is faithful, the other may 
have other casual or concurrent partners, and consequently may be infected or 
become so, passing the infection to the spouse. Women in many countries are 
starting to say “marriage is killing us”.7 Unmarried women, ironically, have a 
greater opportunity of avoiding infection.  
 
The use of sex-workers by men working far from their families is another well-
documented hazard. Men whose lives are often arduous, for example, miners or 




Mother to child transmission 
 
In utero infection is rare. The child is most vulnerable during birth, where transmission rates 
are approximately 30% unless the mother and child are treated with prophylactic 
antiretroviral therapy before birth. During breastfeeding there is a risk of the child becoming 
HIV positive because the virus can be carried in breast milk. However, it has been 
suggested that this risk is greatly reduced if the child is fed breast milk exclusively and 
weaned abruptly because the entry point of the virus is most likely to be small abrasions in 
the baby’s stomach lining caused by poor digestion of non-breast food. Bottle feeding carries 
its own hazards (mainly due to the availability of clean water and the risks of diarrhoea). 
Gender inequality is 
lethal: few women 
are able to refuse 
the advances of 
men. A campaign is 
required to address 
inequality and 
protect the rights of 
women. 
Marriage for women 
is especially 
hazardous. 
Abstention is not an 
option for wives. 
Condom use 
becomes impossible 
to negotiate.  
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Research on this subject has not yet concluded which method has a better survival rate, but 
early indications are that breast feeding may be appropriate in some settings. 
 
Uganda: a case study 
Uganda is often hailed as a success story in combating HIV/AIDS. HIV prevalence dropped 
from 15-30% in 1992 to 4.1% in 2003 among adults aged 15-49.8 In a country with a 
population of around 26 million9, it is estimated that 800,00010 people died from HIV between 
1982 and 2000 (3% of the population). This would account for some of the drop in 
prevalence. A high birth rate (3% pa) further dilutes prevalence rates. Practitioners in the 
field have also suggested that data may not be accurate and prevalence may be worse than 
reported.11  
 
However, it is clear that when compared to similar countries that have had longstanding 
epidemics and where prevalence rates are not dropping, Uganda deserves a great deal of 
credit in its success in combating HIV. Incidence, a much more important indicator, has 
halved in some areas (eg, Masaka).12 In addition, younger groups have much lower 
prevalence than before, another good indicator of progress. 
 
USAID has used Uganda as a case study.13 The conclusions are that the epidemic has been 
reduced through behaviour change, specifically:  
• reduction in the numbers of partners – “zero grazing” – and delayed sexual debut; 
• increased use of condoms by those “moving around.”  
 
Box 2:  Uganda - further ahead on the epidemiological curve 
“Uganda continues to present proof that the epidemic does yield to human 
intervention. Recent HIV infections appear to be on the decline in several parts 
of the country—as shown by the steady drop in HIV prevalence among 15–19-
year-old pregnant women.”14 
 
“The horror of Slim [AIDS] is forcing people to change social habits…..in 
[Kampala] a young housewife with three children declared, with a gleam in her 
eye, ‘my husband stays at home much more. And I encourage him to do so by 
enthusiastically keeping him informed of the latest gossip about Slim victims.’”15 
 
It is generally felt that the reduction in partner numbers was the most important factor in 
reducing prevalence rates, although condom usage probably played a role in maintaining 
low levels (eg, nearly 100% condom usage by commercial sex-workers in Kampala). 
 
Behaviour change was brought about by a combination of factors (in no particular order): 
• Political commitment: Early on in the epidemic the Ugandan government faced the 
HIV/AIDS crisis head-on, and with the help of international donors encouraged 
multi-faceted initiatives to tackle it. Political leaders were encouraged to discuss 
HIV and sex: it became a ‘patriotic duty’ to talk about HIV and to modify behaviour 
in order to protect the population.  
• Advertising campaigns promoting ‘abstinence, faithfulness, condoms’ were clear on 
behavioural risks, but were humorous and appealing rather than ‘preachy’. 
• The government encouraged open personal communication through social and 
family networks (as demonstrated publicly by President Museveni) which increased 
the personalisation of risk, ie, the notion that it could happen to you not just other 
people – that is important if behaviours are to change. 
• Other initiatives were heavily decentralised: local (village) councils were involved in 
forming local committees to promote prevention and address stigma. Faith-based 
organisations also had an important role. 
• Gender empowerment during President Museveni’s regime strengthened women’s 
rights and social standing. 
• HIV education efforts in schools were mainstreamed. 
• Voluntary counselling and testing (VCT) became widely available.  
 
In addition to the interventions, it is also likely that the sheer level of mortality shocked the 
population into protecting themselves.16 
Uganda deserves 
credit for efforts to 
combat HIV.  
 





- ‘patriotic duty’ to 
put HIV on personal, 
family and 
community agendas 
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The cost of these efforts represents excellent value for money. Total donor support for 
HIV/AIDS-related contributions during 1989-98 amounted to roughly $1.80 per adult per 
annum over the period. 
 
 
International response to the epidemic 
“According to UNAIDS, developing countries need £6.6 billion ($12 billion) by 2005 to have a 
fighting chance of halting the spread of AIDS. At the moment, there is only £2.6 billion ($4.7 
billion) in the pot, so a top priority for the international community is to increase the long-term 
funding for developing countries.”17 
 
Many argue that the international response to date is inadequate. The required costs of an 
effective response vary depending on how they are measured and how realistic, universal 
access to antiretroviral drugs is in the face of poor health infrastructures. UNAIDS estimates 
that at least $12 billion is needed annually from 2005; rising to $20 billion by 2007. However, 
the amount available in 2003 was only $4.7 billion – hardly a good indicator of intent. 
UNAIDS contrasts this with the estimated $11 billion spent by the US government 
domestically on AIDS in 2000.18  
 
The figures available are contradictory and are rarely presented on an annual basis.  There 
may also be an element of double counting: low and middle income governments spent $1 
billion on HIV/AIDS domestically in 2002, but how much of this came from bilateral 
agreements with high income countries? UNAIDS estimates that in 2003, high income 
countries were projected to spend $3.6 billion, although it is not clear how they derive this 
figure.  
 
Table 1: Principal contributors to response $ million per annum 2003




Bilateral funding in 2003: 
US (will increase to US$3bn pa from 2004/5) 580 3,000
UK (will increase to US$890m pa from 2005) 450 900
The rest (mainly Europe, Canada, Japan, Australia) 610 600
 
National governments in 2002, assumed 2003 same 1,000 500
Global Fund – estimated pledged average since inception 1,000 1,000
UN agencies including UNAIDS  120 200
World Bank (commitments spread over several years) as at 2004 – 
US$1.6bn 800* 1,000
WHO 850 800
Bill and Melinda Gates Foundation 200 200
Other foundations 2002 140 100
International NGOs 2002 100 100
 
Total identifiable funding flows 5,850 8,400
 
Given the complexity of Table 1, it is probably helpful to explain the roles of the principal 
international players in the epidemic and how they relate to each other. 
 
UNAIDS (Joint United Nations Programme on HIV/AIDS) 
This is a joint initiative between the 22 UN member governments, five major NGOs and ten 
co-sponsoring agencies (UNHCR, UNICEF, WFP, UNDP, UNODC, ILO, UNESCO, WHO 
and the World Bank).  
 
UNAIDS sees itself as having the following roles: 
• Leadership and advocacy for effective action on the epidemic. 
• Strategic information to guide efforts against AIDS worldwide. 
• Tracking, monitoring and evaluation of the epidemic and of responses to it. 
• Civil society engagement and partnership development. 
                                                           
* NPC estimate given rapidity of deployment of each MAP project 
$12 billion rising to 
$20 billion needed 
each year – but in 
2003 only $4.7 
billion available.  
Yet US spent $11 
billion on AIDS 
domestically in 
2000. 
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• Mobilisation of resources to support an effective response.   
 
UNAIDS is an important source of international data on the epidemic. Its 2004 report on 
AIDS is a helpful document. UNAIDS also helps to develop and implement programmes, 
either directly or through related UN agencies. On the ground, the situation sometimes 
seems complicated by the fact that many UN agencies related to development and 
population (eg, UNFPA, UNDP) also handle some HIV/AIDS interventions directly, and 
indeed have mainstreamed HIV/AIDS in much of their work.   
 
UNAIDS is currently doing interesting work in conjunction with the oil company Shell in 
scenario building, a tool that the private sector has found useful in determining strategy. It is 
expected that this will help to inform policy priorities for the global community. Early 
indications are that health and other development issues (social norms, civil society and 
governance) need to be tackled concurrently and not sidelined.  
 
UNAIDS itself does not have a huge spending budget ($125 million per annum), but 
encourages the development of programmes to target HIV/AIDS, such as the World Bank 
MAP programme. According to information supplied by UNAIDS, between 1996-2002 UN 
contributions to HIV/AIDS were much less significant than the large quantities of bilateral 
spending by governments.19  
 
WHO (World Health Organisation) 
The WHO’s gross annual income and expenditure, is around $1.25 billion20. WHO member 
countries provide $750 million of this funding. The Africa regional office receives $250 million 
per annum. In addition, there are specific initiatives around HIV, TB and “communicable 
diseases” that account for an additional $300 million per annum.   
 
WHO is now committed to the ‘3 x 5’ initiative: an ambitious plan designed to ensure that 
three million people are treated with antiretroviral drugs by 2005. This initiative is not the 
responsibility of the WHO alone, although it is spearheading it. Governments and other 
agencies are involved. The treatment of three million people with antiretroviral drugs is likely 
to cost between $3.1-3.8 billion in 2005 if 80-90% coverage is assumed.21  This suggests 
that antiretroviral treatment costs over $1,000 per patient per annum. In countries such as 
South Africa where health infrastructures are already developed, actual experience is 
cheaper ($55022 per patient per annum), but given the requirement to improve many health 
infrastructures, these cost estimates are realistic. The WHO itself is committing $564 million 
cumulatively to 2005.23 The rest must come from other sources. 
 
The ‘3 x 5’ initiative has had a mixed reception. Some people think that without it, treatment 
would still be far too low on the agenda of countries that believe antiretroviral treatment is 
too difficult and where there is still widespread stigma around HIV/AIDS. 
 
Others worry, however, that the ‘3 x 5’ initiative is pressuring some countries, whose health 
problems are not limited to HIV/AIDS, to divert scarce resources away from other vital areas, 
such as diarrhoeal diseases, maternal mortality and malaria.  
 
Global Fund 
Kofi Annan’s proposal of a Global Fund to fight AIDS, TB and Malaria was unanimously 
endorsed in June 2001 at the first UN General Assembly Special Session on AIDS. 
HIV/AIDS groups have welcomed the Global Fund as a more independent and informed 
grant-maker than bilateral governmental aid. The Global Fund states that “the highest 
priority will be given to proposals from countries and regions with the greatest need, based 
on highest burden of disease and the least ability to bring the required additional financial 
resources to address these health problems.” 24  
 
The Global Fund uses Country Co-ordinating Mechanisms (CCMs) to distribute its grants. 
The idea is to keep the central secretariat to a minimum, and devolve responsibility for 
application submission and management to recipient countries. Each country has put 
together its own CCM; in some this equates to the government’s national AIDS council, 
while in others it is a federation of the government, an NGO, and People Living With 
HIV/AIDS (PLWHA) organisations. The CCMs co-ordinate the submission of programmes to 
the Global Fund, and approve them prior to application to the Global Fund itself and its 
Technical Review Panel. The Global Fund admits candidly that the efficacy of the CCMs is 
variable. Improving the CCM system is a priority.25  
 
WHO is committed 
to treating three 
million with ARV 
drugs by 2005. This 
is likely to cost $3- 4 
billion per annum. 
 
But will this take 
scarce health 
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from other problems 
such as malaria, 
diarrhoea and 
maternal mortality? 
Global Fund aims to 
give priority to areas 
of greatest need. 
 NPC HIV/AIDS - global context  February 2005 13 
Kofi Annan originally estimated that $10 billion per annum would be needed, but to date it 
looks like the actual annual spend of the Global Fund may well average out to be only $1 
billion to cover all three diseases. 26 
 
World Bank – MAP 
The World Bank’s most significant financial contribution to the pandemic is from MAP – its 
Multi-Country HIV/AIDS Program for Africa. MAP was launched in 2000, and has so far 
provided over $1 billion to 28 African countries. MAP1 provided $500 million of credits and 
experienced heavy demand. MAP2 was launched in 2002 and was worth a further $500 
million. MAP supports programmes that are complementary to the efforts of others, and 
helps plug unfunded gaps, such as health system development and TB control. It is not clear 
to NPC whether the MAP programme will continue after MAP2. 
 
President’s Emergency Plan for AIDS Relief (PEPFAR) 
The US contribution is likely to increase following President Bush’s pledge in the State of the 
Union speech this year to increase spending on AIDS to $15 billion in the five years 2004-8. 
The White House claims this will prevent seven million new infections, 60% of the 
projected 12 million new infections in the 14 target countries. It aims to provide 
antiretroviral drugs for two million HIV-infected people and care for ten million HIV 
positive individuals and AIDS orphans.27 
 
Of the $15 billion, 55% will go into treatment, 20% into prevention, 15% into care for the 
dying and 10%28 into protection of orphans. In practical terms, PEPFAR will direct the funds 
in three directions: 
• $9 billion over the period will go on new resources for ‘Focus Countries’.*  
• $5 billion will augment existing bilateral programmes involving USAID and the 
Department of Health and Human Services.   
• $1 billion will contribute to the Global Fund. 
 
The Bush administration’s budget for the 2004 fiscal year only recommends $1.7 billion for 
the initiative, rather than the $3 billion implied by the pledge and corresponding bill. More 
recently, the House of Representatives trimmed the overall International Aid budget; this will 
inevitably have a knock-on effect on the $15 billion.  
 
Nonetheless, these funds are a significant contribution should they materialise and if they 
are well directed. Large amounts of aid can be difficult to digest, however, and when the 
administration costs of implementation are taken into account, impact on the ground is 
sometimes diluted. The funds are available to NGOs, faith-based groups, public-private 
partnerships and governments. On the one hand, this is to be welcomed because it provides 
funding flexibility. On the other hand, many are worried this money may create parallel 
structures in environments where capacity is scarce. The role of USAID in helping to direct 
funds sensibly will be important.  
 
There is concern in some quarters that the US prevention programmes over-emphasise 
abstinence and fidelity: they simplify some of the issues in regions where behaviour change 
is difficult to achieve. In addition, NPC understands that the US is unlikely to allow the funds 
available for antiretroviral drugs to be used to purchase generic drugs produced outside the 
US. This will have significant implications on how far the funds will go.29 
 
USAID has delivered $3.2 billion of funding for HIV/AIDS since 1986, and is a partner in the 
delivery of the PEPFAR programme. It also has grant programmes of its own to support 
community responses and faith-based groups, but these are on a relatively small scale ($50 
million).30  
 
DfID – Department for International Development, UK 
The UK government announced in July 2004 that it is committing £1.5 billion ($2.67 billion) † 
to HIV/AIDS-related work between 2005 and 2008. This is a massive contribution relative to 
other governments in the developed world, whose contribution amounts to roughly $608 
million in 2003. 31 The UK government has identified several strands that it will support: 
                                                           
* Botswana, Cote d’Ivoire, Ethiopia, Kenya, Mozambique, Namibia, Nigeria, Rwanda, S Africa, Tanzania, 
Uganda, Zambia, Guyana, Haiti, Vietnam 
† US$1.78:£1 used throughout (rate of conversion as at 15th September 2004 using www.xe.com 
universal currency converter) 
 
Budget shortfall: $3 
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only $1.7 billion 
available. 
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• Action that prioritises women, young people and vulnerable groups; 
• $267 million of the budget to be spent on the needs of orphans and vulnerable 
children, particularly in Africa; 
• $140 million to the Global Fund; 
• $64 million to UNAIDS; 
• $142 million to support UNFPA. 
 
DfID is a strong advocate of improved donor cooperation and harmonisation of efforts. It 
wants to see one agreed “action framework”, single national AIDS authorities and monitoring 
and evaluation systems, and, where possible, single funding mechanisms to channel 
bilateral funding.   
 
In January 2005 the UK government called for $100 billion dollars of support for an 
International Finance Facility for HIV/AIDS. In particular, Gordon Brown (UK Chancellor of 
the Exchequer) wants the spending for research on a vaccine to double in order to 
accelerate its discovery. 
 
Bilateral donors and technical support 
A number of countries have bilateral programmes with developing countries. These 
programmes amounted to $608 million of funds for HIV/AIDS in 2003, mainly from Europe, 
but with some contributions from Canada and Australia. 32  A number of these countries also 
provide technical support as well as funding, including the German Technical Cooperation 
(GTZ) and the Belgian Technical Cooperation (BTC).  
 
GTZ specialises in cooperating with international clients in sub-Saharan Africa. A 
management team of more than 20 experts at the German head office and in four regional 
coordination units works hand in hand with some 150 international experts and 2,000 local 
professionals at country level, focusing on health, rural development, education, conflict and 
crises.   
 
BTC operates in 14 sub-Saharan countries. It carries out projects with partners in developing 
nations on behalf of the Belgian government and other donors. Assignments may be 
accepted from other organisations active in the development cooperation sector, such as the 
European Union, World Bank and the King Baudouin Foundation. 
  
The Gates Foundation and others 
The Gates Foundation’s Global Health Programmes, established in 1994, have so far 
amounted to $3.8 billion, of which $1.3 billion has been dedicated to HIV, TB and 
reproductive health. A further $1.5 billion has been dedicated to ‘global health strategies’, 
some of which may benefit the developing world.  NPC estimates that in 2003, the Gates 
Foundation contributed around $200 million to HIV/AIDS and TB initiatives33. By the end of 
the first half of 2004, it seems that it has already exceeded this level, not least due to a $50 
million donation to the Global Fund to top up an earlier donation of $100 million in 2002.  
 
Apart from its size, the Gates Foundation is interesting because it supports international 
medical initiatives to develop microbicides, vaccines and other important clinical 
developments. Notable clinical grants since 2002 have been $60 million for the International 
Partnership for Microbicides and $83 million to the Aeras Global TB vaccination foundation. 
In 2001, Gates provided $100 million over five years to fund the International AIDS Vaccine 
Initiative. Some of the programmes it supports demonstrate the Foundation’s considerable 
appetite for risk, and a willingness to fund initiatives over a protracted period. It is quite 
possible that some of the more unusual trials and civil society initiatives benefiting from 
Gates funding may turn up exciting developments.   
 
NPC estimates that other US foundations have contributed $140 million to efforts in 2002. 
These include organisations such as Bristol-Myers Squibb,34 the Henry J. Kaiser Family 
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International NGOs and faith based organisations (FBOs) 
There are a number of important NGO groups working to tackle HIV. The spending by these 
NGOs amounts to about $95.5 million in 2002.35 Examples of NGOs undertaking important 
HIV work in Africa are Medecins Sans Frontieres (MSF), Save the Children, ActionAid, 
African Medical Research and Education Foundation (AMREF), Catholic Agency for 
Overseas Development (Cafod), Christian Aid, Care International, World Vision and Oxfam. 
Other smaller international NGOs also contribute to efforts. 
 
Some of their work is focused on particular country programmes, but they may also 
contribute to international efforts, for example, MSF’s and Oxfam’s advocacy work around 
drug access. Work may be important in developing international knowledge: AMREF’s 
evaluation of their peer education programmes would be a case in point. Other NGOs are 
increasingly adopting ActionAid’s “Stepping Stones” approach. 
 
The big international NGOs are not present in all countries, and their performance can vary 
on a country by country basis.  
 
It is also important to recognise the role of faith-based organisations and churches in the 
epidemic. Many of their activities (care of orphans, care of the infected) are valuable, 
particularly in the absence of other civil structures. However, in some areas, faith-based 
organisations or churches have contributed to stigma and negative attitudes about sexuality 
and have therefore hampered prevention.  
 
The Roman Catholic Church and HIV 
 
The official stance of the Vatican, as articulated by the president of the Vatican's 
Pontifical Council for the Family, Cardinal Trujillo, is that “the AIDS virus is 
roughly 450 times smaller than the spermatozoon. The spermatozoon can easily 
pass through the ‘net’ that is formed by the condom.36” Consequently the 
Catholic Church officially continues its ban on condom use regardless of its 
potential for saving lives.  
 
The WHO has condemned the Vatican's views, saying: “These incorrect 
statements about condoms and HIV are dangerous when we are facing a global 
pandemic, which has already killed more than 20 million people, and currently 
affects at least 42 million.”  
 
Not all Catholics support the Vatican on its position. Theologically, many 
Catholics regard the Vatican’s position as tenuous, citing the principle of ‘lesser 
of two evils’ in determining whether it is better to prevent death of a living adult 
(through the use of condoms) or allow a future life (by eschewing contraception) 
despite the cost of an adult life. These Catholics recognise that abstinence may 
not be an option for some, nor indeed do they always believe that abstinence is 
desirable if couples in a now faithful marriage are discordant. 37 
 
Cafod (the Catholic Agency for Overseas Development) disagrees with the 
Vatican and “does not support programmes that give false or misleading 
information about prevention (for example that HIV will inevitably pass through 
holes in latex or that condoms contain HIV”. It also “actively supports on-going 
theological reflection on the implications of prevention for HIV”. 38 
 
Some Catholic bishops in the developing world take a similar stance to Cafod, 
but not all. Unfortunately there remain large parts of the clergy who support the 
Vatican’s position, which can undermine the prevention efforts of other NGOs. 
 
Against this, it is generally recognised that faith-based organisations, including 
the Catholic Church, have done much to help the plight of orphans and 
vulnerable children in the epidemic. Catholic mission hospitals have often been 
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Medical advances and research 
A number of European and US medical institutes are working hard to advance clinical 
prevention and treatment of the disease (of which more later); this work is taking place on a 
number of fronts.  
 
Prince Leopold Institute of Tropical Medicine in Antwerp and the London School of 
Hygiene and Tropical Medicine (LSHTM) are undertaking numerous research initiatives 
into HIV/AIDS, TB and sexually transmitted infections (STIs) from both clinical and social 
standpoints, including randomised studies of STI treatment. They are also trying to 
determine how best to disseminate best practice and clinical findings to practitioners in 
resource-poor environments, because transferring knowledge from the first world to 
developing countries is frequently a challenge. The UK’s Medical Research Council (MRC) 
regularly partners-up with local research institutes. In the US, the Centers for Disease 
Control, the University of North Carolina, and Columbia University are important research 
institutes.  
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Section 2: Responses to the HIV/AIDS pandemic 
 
In response to the HIV/AIDS pandemic, a substantial sector has emerged. The sector 
operates at international and national levels to tackle the crisis from a range of 
angles. Much can be done to help those infected and affected by HIV/AIDS, on a large 
or small scale. Private philanthropists will find activities that are suitable for support. 
NPC would always urge collaboration between donors and agencies trying to help in 
order to maximise effectiveness. This section explains the main elements of the 




The causes of the HIV epidemic are complex, and there is no single solution. The response 
is complex, but broadly speaking, the war is being waged on the following multi-pronged 
fronts:  
• prevention and education;  
• people with HIV/AIDS: treatment and care; 
• people affected by HIV/AIDS.39  
  
These are by no means mutually exclusive, and projects often involve two or more of these 
approaches. Favoured methodologies of combating HIV/AIDS are increasingly holistic.  
 
This section will attempt to disentangle the various approaches, but because responses may 
be targeted at different issues and sectors of variable populations, they do not necessarily sit 
in neat boxes.  
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*VCT (voluntary counselling and testing); STI (sexually transmitted infections); PMTCT  
(prevention of mother to child transmission) 
 
As the report stated earlier, the epidemic is cyclical and breaking the cycle requires activities 
on a number of fronts. Figure 3 shows a person’s progression from being healthy and HIV 
negative (top right-hand corner) to becoming HIV positive with AIDS, and then goes on to 
show the effect on families and communities.  
 
Figure 3 excludes some of the general development efforts (health care, education, 
infrastructure, income generation, economic improvements and capacity building) also 
needed to support efforts to break the cycle. 
 
Breaking the cycle 
of infection and 
poverty requires a 
concerted effort on 
several fronts. 
 NPC HIV/AIDS - global context  February 2005 18 
All these responses should be placed in the context of the conditions found in resource-poor 
countries, which will also vary between areas. Below are some key themes to bear in mind 
when considering any intervention. 
 
• Social drivers relating to issues, such as stigma, behaviour, attitudes to risk, 
religious and cultural beliefs. 
• Gender, in particular attitudes to women and vulnerable groups. 
• Economic conditions and consequent opportunities for income generation. 
• Health systems: to what extent do they exist and what is the level of medical 
knowledge in the particular areas? 
• Infrastructure: access to transport, water and such-like. 
• Education: is the community literate? 
• Population mobility: is the community in a state of flux? 
• Civil society and local stakeholders: what do people actually want? 
 
It is difficult to encourage non-risky sexual behaviour in environments where general 
expectations of life are extremely low.  It may be necessary to consider how people’s 
expectations can be improved, so they have incentives to adopt non-risky behaviour. 
Similarly, it may be tough to reduce levels of sexually transmitted infections through a mass 
treatment programme if a community is unstable and half its population is moving in and out 
of the zone being treated.  
 
It is important that HIV/AIDS is included in measures at all levels: education, community 
development, national programmes, private and commercial sectors and NGO activities. 40 
 
The state of a country’s health system is fundamental to the delivery of HIV/AIDS measures. 
The importance of basic primary health care delivery cannot be over-emphasised: it affects 
not only the care and treatment of patients, but also provides an opportunity to get across 
AIDS prevention messages and motivates people to establish their HIV status and to change 
behaviour.  
 
Where data on Central Africa’s experience are absent, interesting data are often available 
from East Africa, an area that is further ahead on the epidemiological curve. Lessons can be 




The best place to tackle any virus is at the point of infection. The effects and impact of 
averting infections are far-reaching. Numerous economic and social costs are avoided if 
infections are prevented, including the expense of treating sick people, lost earnings 
capacity and productivity, loss of skills and knowledge, and social ills associated with a lack 
of carers for children. 
 
If a sexually active individual does not get infected then this results in protection for their 
partners and partner’s partners and so on. For children, the avoidance of infection 
represents an opportunity for a healthy life. Although antiretroviral treatment is a desirable 
tool in tackling the effects of the epidemic, the fact remains that it is costly and as the 
numbers of people infected and developing full-blown AIDS increases, these demands will 
grow. Prevention efforts try to stem these demands by reducing the number of people 
infected. 
 
The focus of prevention should be stopping the most infections for the minimum cost, and 
therefore a useful method of measuring results is the cost “per infection prevented” (pip), 
which is analogous to the cost per successful user. It should be noted, however, that as the 
only conclusive way of preventing infection would be a vaccine; the initiatives discussed may 
not prevent people from ever being infected, although they might delay infection or reduce 
the likelihood of future infection. Nonetheless, although these prevention initiatives do not 
make individuals immune to HIV, they slow the rate of infection through the population. 
 
This section covers the prevention of mother to child transmission, blood security and 
needles, as well as medical advances such as vaccines and microbicides. It then goes on to 
the extremely complex matter of sexual transmission and the numerous attempts to reduce 
transmission via this route. These overlapping initiatives include treatment of sexually 
transmitted infections, voluntary counselling and testing, education and condom distribution. 
 
 
It is difficult to 
encourage non-risky 
sexual behaviour 
where people have 
no hope and low 
self-esteem. 
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Prevention:  prevention of mother to child transmission of HIV (PMTCT) 
One of the most heartbreaking forms of transmission of HIV is from mother to child. This can 
occur in utero, during birth and through breastfeeding. 
 
In utero infection is rare. The child is most vulnerable during birth, where transmission rates 
are approximately 30%. The standard method of preventing mother-to-child transmission at 
birth is a dose of Nevirapine to the mother at the start of labour and then to the newborn. 
This halves the risk of transmission to 15% and the cost of the drug is only about $441. A full, 
highly active antiretroviral drug (HAART) regime in the final trimester of pregnancy and 
during labour reduces the risk of transmission to less than 1%, but requires clinical 
supervision similar to a normal antiretroviral drug programme.  
 
It is a cruel irony that successful PMTCT programmes may exacerbate the orphan problem 
because children become more likely to survive their parents. The outcomes for mother-to-
child transmission prevention interventions are rather hollow if the mother is subsequently 
left to sicken and die early in a child’s life and if there is inadequate social care in place. On 
the other hand, a sick child is a greater burden to the parent while living (and the remaining 
family) than a healthy one. Ideally, PMTCT programmes should include family planning so 
that further pregnancies (and the concomitant risk of accelerating the onset of AIDS and the 
problem of future orphans) are avoided. 
 
The total cost of administering PMTCT varies according to whether the infrastructure to 
deliver the drugs already exists. There are debates over the probabilities of transmission 
with and without Nevirapine, and studies show a range of costs per infection prevented (pip), 
from $21 to $32742. The provision of highly active antiretroviral therapy (HAART) for the 
necessary period would cost roughly $25043. The pip cost is therefore just over $86244.  
 
The role of breastfeeding in the transmission of the virus is not fully understood. It may be 
that exclusive breastfeeding carries a sufficiently low risk of transmission, making it 
preferable to formula milk mixed in less than sterile conditions. A six-month formula regime 
costs $72 per family, unaffordable for parts of the population. If transmission risks through 
breastfeeding are assumed to be 10%45, then this implies a pip cost of $720 (one South 
African study estimates costs as high as $6,680 pip). Formula milk may also create stigma 
for the family46. Scientists are currently researching the effect of antiretrovirals on 
transmission through breast milk.  
 
 
Prevention:  blood security, needles  
Blood security is important in preventing transmission of the virus within hospitals and the 
health system. There are data that emphasise its cost effectiveness: $40-246 pip47. In many 
sub-Saharan countries blood security remains an unresolved issue. Intravenous drug use is 
not yet a reported problem in sub-Saharan Africa, except for on the east coast of Kenya and 
Tanzania where it may become a problem. However, transmission of the virus through poor 
needle sterilisation (in immunisation for instance) has been reported sporadically and good 
practice is important in any public health programme.  
  
 
Medical advances in prevention: vaccines and microbicides 
Vaccines 
The holy grail of AIDS research is a vaccine that would enable the immune system to 
eradicate HIV as soon as infection occurs. Michael Gottlieb, the man who first identified 
AIDS in 1981, predicts that “by the year 2010, several of the most promising HIV vaccine 
candidates could be under study in controlled clinical trials . . . by 2021, one or more of 
these could have reached a level of effectiveness and safety that would allow its 
administration”.48 This is a long way off. If HIV continues to spread at the rate 
epidemiologists predict, then long before a vaccine is ready, Asia may be facing a pandemic 
which dwarfs that currently underway in Africa.   
 
There are currently 30 candidate vaccines being tested in small-scale trials. The 
International AIDS Vaccine Initiative (IAVI) is calling for $1.3 billion to be spent annually, 
but in 2003 funding was only $650 million per annum, less than 1% of total spending on all 
health products. The private sector has little incentive to contribute to efforts: only 15% 
comes from this source, 67% comes from governments (mainly the US), and the rest from 
philanthropists. The Gates Foundation contributed $100 million in 2001.   
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Microbicides (contained in vaginal gels or similar product) are an alternative method of 
prevention to vaccines and condoms, and would give women more control over their own 
protection. As discussed later, giving women greater power to protect themselves has 
enormous potential in slowing the spread of the virus. There is no microbicide of proven 
efficacy yet. 
 
The Gates Foundation committed $60 million to the International Partnership for 
Microbicides (IPM) in 2003. IPM was formed out of the Microbicide Initiative funded by the 
Rockefeller Foundation in 2000 and supports and coordinates international efforts, helps 
with advocacy and regulatory affairs, and also stimulates forward thinking around the 
distribution of microbicides. In 2000, research undertaken by the London School of Hygiene 
and Tropical Medicine concluded that 2.5 million infections could be averted in a three year 
period49, and 27% – nearly 700,000 – of these would be in sub-Saharan Africa.50 
 
Development of effective microbicides will probably cost $1 billion. The Medical Research 
Council in South Africa is predicting their commercial availability as early as 2008 (although 
they will be only 50% effective51). However, it is estimated that the $1 billion cost would save 
$3.7 billion in healthcare – excluding the expense of antiretroviral drugs. Therefore, the raw 
economics are extremely attractive, let alone the profound humanitarian and social benefits. 
If one assumes that antiretroviral treatment costs $500 per patient per annum, then 
microbicides would save $12.5 billion over a ten year period.  
 
There are a number of organisations conducting clinical trials, including the Medical 
Research Council (MRC) in the UK. The MRC is a partner within the Microbicides 
Development Programme which is heavily supported by DfID to the tune of £16 million ($29 
million) over five years and which has seven pilot trial sites in Africa.  
  
 
Prevention: behaviour change relating to sexual transmission – education etc. 
“The mainstay of prevention programmes involves changing behaviour, improving access to 
condoms and decreased [clinical] vulnerability of HIV. Extensive research has shown that all 
prevention strategies need to take into consideration and address: poverty, discrimination, 
gender inequality, unemployment, illiteracy and cultural practices, all of which enhance 
vulnerability to HIV infection”.52  
 
Prevention strategies, including behaviour change, are difficult to analyse. Conservative and 
religious groups debate them fiercely, wanting to pursue strategies around morality. Others 
want pragmatic solutions. NPC believes there is too much polarisation around these issues 
and that there is no “one size fits all” – a range of approaches to suit circumstances is best.  
 
Factors driving the heterosexual epidemic 
It is helpful to explain the factors that drive the HIV epidemic and to place them into social 
context. Such drivers have implications for prevention strategies.53 
 
Frequency of sexual contact: The estimated rate of HIV infection per sex act between 
discordant couples is surprisingly low. Between an HIV positive man and an HIV negative 
woman there is a 2% risk of infection, but only 1% when the woman is positive and the man 
negative.54 Of course, other conditions, such as the presence of sexually transmitted 
diseases, affect this rate. Regular intercourse raises the probability of infection, which is why 
there is high risk of transmission between discordant couples in steady partnerships. A 
discordant couple having unprotected sex every day for a year has a 99% chance of viral 
transmission. This likelihood drops markedly if contact is sporadic.  
 
Levels of prevalence affect the risk of transmission: in areas of lower prevalence, 
occasional casual sex with different partners may, ironically, be safer than regular sex with 
long term partners where one of them is HIV positive. In areas of higher prevalence, casual 
sex is hazardous, and this is clearly a high risk behaviour that prevention strategists need to 
target. However, in areas of high prevalence, the riskiest relationship is a steady/regular long 
term concurrent sexual one, an issue increasingly raised by those working in prevention.  
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Concurrent sexual relationships (where someone is having sex with more than one 
partner) are common in sub-Saharan Africa and have particular consequences. If one 
person in a sexual network becomes infected, the mathematical likelihood of transmission to 
other members is high55. Prevention messages must address this. In Uganda, the president 
and national awareness campaigns focused on “zero grazing” (the promotion of 
faithfulness), which helped reduce the prevalence of HIV/AIDS. 
 
Gender and income access is another important driver. One of the key difficulties for 
women is that they rarely control economic assets, such as land. They are frequently 
dependent upon men, either within marriage or in other sexual arrangements. Women may 
be subject to a degree of control within relationships, including the most mundane activities: 
some women need their husband’s permission to visit a doctor.56 Until the economic and 
social balance of power is redistributed, it will be difficult for women to be the “agents of 
change” in sexual and other behaviour. At the same time, society’s expectations of men (that 
they are experienced and knowledgeable about sex) prevent them from seeking information 
and guidance on what might be preferable behaviours.  
 
The picture becomes even more difficult when one takes into consideration the small 
incomes for either sex in sub-Saharan Africa. People have to migrate in order to find work 
(removing them from their family structures), or engage in sex work in order to feed families. 
 
Alcohol and its effect on behaviour and attitude to risk is an area of increasing concern to 
those in this field.  
 
Sexual practices also affect the risk of transmission per sex act. The use of vaginal drying 
agents was mentioned earlier. A new hazard is anal sex. It is increasingly practised in order 
to avoid pregnancy. In some cases, it is mistakenly believed that anal sex is also a way to 
avoid infection with HIV, which is ironic, given that it is actually much riskier.  
 
General factors affecting behaviour also include poverty, migration, political instability and 
low levels of education.  
 
Population groups 
It is helpful to segment the population into different groups: 
 
High risk groups might transmit the virus to members of the wider population so are an 
important segment.  This is particularly relevant when prevalence is not high but “hot spots” 
of high prevalence exist, which might affect the wider population in due course. Messages of 
abstinence and fidelity may not be relevant to high risk groups, such as commercial sex-
workers, but it may be possible to get them to use condoms regularly (as was the case with 
the sex-workers in Kampala, referred to earlier). This avoids spreading the epidemic to other 
segments of the population.  
 
People working far from home (for example, truckers, miners, and the military) are often at 
higher risk of contracting the virus and bringing it back. Experts are paying increasing 
attention to people who are internally or externally displaced, particularly in refugee camps. 
Men who have sex with men are vulnerable to the virus, and may infect their wives. 
 
The age of sexual debut has an important bearing on the development of epidemics. If one 
examines the prevalence data in terms of age groups, there is often a window of opportunity 
to protect the young generation from infection. However, incidence rates among young 
people are alarming. The later the sexual debut of young people, the greater the chance of 
avoiding infection. Young girls may enter sexual partnerships with older men, in 
circumstances where their ability to negotiate safe sex is limited. It is necessary to support 
programmes involving older men to change their behaviour towards, and treatment of, 
younger girls. Abstinence and fidelity messages will not have high take-up if they are 
directed at the young women alone.   
 
Spouses, especially women are now recognised as a group with its own risks. As noted 
earlier, a steady relationship does not provide security. It is extremely difficult to persuade 
married couples, or those in long term relationships, to use condoms habitually, and may not 
be appropriate to do so. Using condoms can be inconvenient within the marital home, and 
marriage assumes trust (justified or otherwise) between the parties. The ‘institutionalisation 
of mistrust’ through habitual condom usage is not seen as palatable. In addition, procreation 
is often desired, preventing condom use.  
 
It is preferable, epidemiologically, to persuade married people to remain faithful. As 
discussed earlier, the concurrent sexual partnerships commonly found in Africa are 
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important viral vectors and if these networks can be broken, then the virus is less likely to 
spread. President Museveni recognised this in Uganda, and also that men were likely to be 
the prime agents behind concurrent sexual partnerships.  
 
If a couple is already discordant (one of the partners HIV positive, one negative), 
subsequent fidelity can be considered irrelevant. Young women who marry older, sexually 
experienced men are often at risk. Voluntary counselling and testing is a vital component of 
any strategy as this will identify whether couples are discordant. If one partner is HIV 
positive, then condoms are the best solution. If the HIV positive partner is on an antiretroviral 
programme, which significantly reduces viral load, the risk of HIV transmission is lower. 
 
Older men who are influential within their communities and are economically successful, 
and may also have a medical history of sexually transmitted diseases and HIV infection, 
often have relationships with much younger women and infect them. On the other hand, they 
can also be agents of change if they publicly support less risky behaviours (President 
Museveni) or try to protect young women from sexual violence (Chief Makoni in Zimbabwe).  
 
Interventions addressing these factors and populations groups 
Box 3:  ABC – Abstinence, Being faithful, using Condoms 
 
The traditional prevention methodology is based around “ABC”, which stands for 
Abstinence, Being faithful, using Condoms. PEPFAR favours this methodology, 
and emphasises the first two aspects.  
 
However, ABC only works in some circumstances. It is a controversial approach 
– some experienced HIV/AIDS practitioners are concerned that ABC does not 
address issues such as gender and income access seriously enough, which 
reduces its efficacy57. It is more difficult to achieve good results from prevention 
strategies if the social and moral values of a community are not well understood.  
 
However, the application of ABC often involves attempts to change behaviour, 
which is useful when used alongside other strategies.  
 
 
Education and behaviour change  
 
In any intervention, the complex cultural issues of the target population need to be well 
understood, and the agents of change identified. Are they local leaders, clerics, traditional 
healers, initiators, media, peer groups, family or social networks? How are gender issues 
addressed? How can the next generation be protected, particularly if not all of it is attending 
school?  It is necessary to engage both sexes in behaviour modification: targeting men (and 
boys who will become men) is important in breaking the cycle of gender inequality in sexual 
relations.   
 
Interventions that do not attempt to understand these subtleties are doomed to failure. 
Experts also argue that risky sexual behaviour does not necessarily stem from an ignorance 
of biological facts but rather a failure to “internalise” risk, in other words, to understand the 
implications of such behaviour and to appreciate that it affects oneself, not just everyone 
else. This too has implications for behaviour change strategies. 
 
National campaigns: It is difficult to measure the efficacy of national media campaigns, but 
they are important. Where television is widespread, soap operas can cover a wide range of 
HIV issues. In poorer areas where people only have access to radio, advertisements and 
radio soap operas are similarly helpful. Billboard campaigns are widely used, although the 
population needs to be literate. In South Africa, a sophisticated branding strategy (LoveLife) 
directed at youth is still being evaluated, but in the townships there are already indications of 
success. Even if it is difficult to quantify the direct effect of national campaigns on behaviour 
change, it makes life simpler for those carrying out specific programmes: they find it easier 
to discuss sensitive issues, and find themselves pushing ‘at an open door’.  
 
There appear to be no statistics determining the pip cost of national campaigns, despite data 
relating to general awareness after individual campaigns, which may be a useful indicator.58 
 
Community education: There have been intensive efforts to change attitudes within 
communities, particularly towards gender. One such example is Stepping Stones, an 
initiative promoted by ActionAid. It develops a sense of responsibility to partners within 
relationships through group discussion, workshops and other participatory tools.  
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Education in schools and early education: Schools must teach children biological facts 
about AIDS and its prevention. Schools can help to repeatedly reinforce messages. 
Education has a role to play in teaching children how to care for those with AIDS, and 
teachers are often vital supporters of children who are bereaved or caring for a sick parent. 
HIV/AIDS education needs to target younger children, particularly as they may be in contact 
with AIDS patients; they are also at risk from sexual abuse. Gender issues, specifically the 
right and ability of girls and women to ‘say no’ or negotiate safe sex need to be addressed 
early. 
 
Peer education among adolescents: Peer education projects are a promising way of 
changing behaviour, and have been well-received in a number of areas. In South Africa the 
cost per user of youth education programmes is $15-30. Reliable data on the pip cost of 
peer education programmes are not yet available, and so far there is no hard evidence that 
incidence rates have changed. However, projects are still in their early days and it is likely it 
will take more than five years to see benefits.59 Besides, educating people about HIV 
prevention gives them a better chance of protecting themselves.  
 
Because sexual abstinence may not be realistic, the success of an education programme 
will be flawed if children and teenagers cannot get hold of condoms. They also need to 
receive treatment for sexually transmitted diseases, voluntary counselling and testing for 
HIV, and be encouraged to disclose their HIV status. HIV positive people must be supported 
and protected from stigmatisation.  
 
Box 4: MEMA kwa Vijana:* Randomised controlled trial of an adolescent sexual 
health programme in rural Mwanza, Tanzania60 
 
A group of nearly 10,000 adolescents was recruited from 20 trial communities 
and divided equally between those who received intervention and a control 
group. Intervention occurred in four major ways:  
• in-school sexual and reproductive health education, provided by a 
mixture of teachers, health workers and 2,000 peer educators 
• youth-friendly reproductive health services 
• community-based condom promotion and distribution 
• community activities. 
 
The project measured HIV incidence, genital herpes, STIs and pregnancy. It also 
assessed reported knowledge, attitudes and sexual behaviours.  
 
The reported knowledge, attitudes and sexual behaviour outcomes were 
encouraging, and showed that there is much value in this project. 
 
However, the biological outcomes were inconclusive and showed no clear 
decrease in HIV infection rates. There may be a number of reasons for this: 
because the overall incidence rates were numerically low (only 45) it is difficult to 
draw statistical conclusions from the sample. It is hard to state categorically that 
the control communities had no interventions – the testing alone would have had 
an effect. Also, three years is a short time in which to measure results –  
probably too soon, particularly from the highest risk age groups that would have 
benefited from only one year of intervention (40% of the group). 
 
It will be interesting to see the results of future biological testing if the 
interventions are continued. The main conclusion to be drawn is that behaviour 
change may not happen quickly, and that the effects of behaviour change may 
take a number of years to be visible. 
 
The Tanzanian government started this research project in the late 1990s. It was 
supported by the EC, DfID, Irish government, MRC and UNAIDS. Since 
implementation, AMREF has been the implementer with the government, with 
collaboration from the LSHTM. The full project cost $880,000 and was conducted 
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Condoms  
 
To be effective, condoms need to be used in a high proportion of sex acts. It is easier to 
persuade people to use condoms in casual sexual relationships than in long term ones, 
because using them can be seen as a sign of promiscuity, or lack of trust.61 Getting 
condoms to those who have casual or commercial sex is a useful way of preventing the 
spread of HIV. Condoms are not always available in resource-poor environments, and are 
unlikely to be used where procreation is desired.  
 
There are few recent or satisfactory statistics on the cost-effectiveness of male condom 
distribution. However, a study of Kenyan sex-workers with access to male condoms and 
treatment for sexually transmitted diseases showed this scheme was extremely cost 
effective at $12-18 pip.62 It is difficult to determine how consistently they are used in the long 
term, and to what extent other factors in a distribution programme (eg, general health 
education and treatment for sexually transmitted diseases) might affect transmission rates.  
 
In Kenya, a study on female condom distribution showed a range of costs depending on 
whether the target group was sex workers ($290 pip) or medium risk women ($2,300 pip). 63 
This wide range reflects the number of occasions a woman is exposed to the virus and, 
therefore, the probability of being infected. 
 
In populations where prevalence is low and most noticeably present in high risk groups (eg 
commercial sex workers, truck drivers), targeting that particular group is a cost effective 
containment measure, but education and general health must also be provided. Results are 
better if condoms can be obtained from user-friendly sources. It is important to note that 
while these figures show condoms have a low pip cost, condom promotion may not work in 
all circumstances. 
 
Voluntary counselling and testing (VCT) 
 
Most medical initiatives directed at AIDS include voluntary counselling and testing (VCT). 
Early detection of HIV improves medical and psycho-social support for individuals. There is 
also the added benefit that counselling persuades individuals to disclose their HIV status. 
 
In 35 recent studies significant reductions in risky behaviour were noted among individuals 
who tested positive.64 It is estimated that in East Africa, VCT programmes avert one case of 
HIV infection for every 10 people accessing them.65 Individuals testing negative are given a 
reason to modify behaviour and protect themselves. 
   
VCT is rarely successful when offered in isolation but is valuable as a component of a 
programme addressing issues of care, socio-economic needs and stigma. The availability of 
PMTCT (described below) is a powerful incentive for pregnant mothers to be tested. VCT 
needs to be offered continuously: it should not be a one-off test, but should be taken at 
regular intervals to reconfirm negative status and reinforce beneficial behaviours. 
 
Evidence from Tanzania and Kenya in 2000 shows a pip cost of around $460.66 VCT has a 
low hit rate in terms of infections prevented but it costs just $22-27 for each user. It also 




Prevention: treatment of sexually transmitted infections (“STIs”) 
 
Transmission of HIV during sex is not automatic, particularly between healthy individuals. 
Sexually transmitted infections increase the risk of HIV transmission although it is difficult to 
accurately measure the difference in probability because of “co-factors”. In the absence of 
STIs, the probability of transmission of HIV from male to female is 2% per sexual contact. In 
the presence of STIs, including ulcers, this probability increases to 6%, according to one 
study.67 Although this implies a threefold increase in risk per sexual contact, because of 
other correlating factors (eg, behaviour) within the test group the actual increase in risk per 
sexual contact is more likely to be tenfold.68 STIs are widespread in Africa and accompany 
risky sexual activity. 
 
It makes clinical sense, therefore, to try to tackle STIs, particularly genital ulcers and herpes 
simplex.  A comparison of three studies in Tanzania and Uganda69 finds the treatment of 
STIs is most likely to have greatest impact on HIV incidence among populations of highly 
sexually active individuals. As the epidemic progresses, more HIV infections occur in stable 
relationships with lower STI prevalence, so although the treatment of STIs remains useful, 
its impact is less significant.  
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A clinic for sex-workers in Kinshasa set up in 1988 demonstrated that long term, consistent 
management of STIs among a high risk group significantly reduces HIV prevalence. In this 
case the rate fell from 35% in 1988 to 12.4% in 2002. 70 
 
A 1997 study of STI control programmes in Tanzania showed costs of $200 pip.71 A Kenyan 
study even estimated that a combined STI treatment and condom distribution programme for 
sex workers in Kenya cost only $15 pip.72 It is unclear whether such incredible cost-
effectiveness can be replicated today when prevalence is more widespread. However, STI 
treatment is undoubtedly useful and initiatives that have a medical component should 




There is currently a great deal of debate as to whether male circumcision can reduce the 
spread of HIV. An observation of prevalence rates in populations that practise circumcision 
versus those that do not suggests a correlation. However, while there is some clinical 
explanation as to why this may be the case, it is not conclusive. There may also be social or 
behavioural co-factors inhibiting the spread of HIV.  
 
Many social scientists do not favour the introduction of circumcision. They fear that it may be 
seen as a failsafe protection measure, which would counteract efforts to introduce behaviour 
change. They are also concerned that circumcision has its own hazards – unsterilised tools, 




Programmes of prevention have the qualitative benefit of introducing the possibility of risk 
reduction to individuals and this empowers them to make choices. Each time an infection is 
averted; future infections from the would-be carrier are also avoided.  
 
It is important to note that prevention initiatives, particularly those relating to behaviour 
change, work best when conducted in an environment where care (be it medical, 
psychosocial or economic) is available for people with AIDS and where communities 




People with HIV/AIDS 
The better the care of people with HIV and AIDS, the longer they live and the higher their 
quality of life. The patient requires less attention from their children or parent, and may even 
be able to remain in employment. Children of people with AIDS who are well-cared for can 
continue their education.  
 
Organisations must address stigma: people with AIDS are often thrown out of homes and 
communities. If they support patients and educate communities, this will reduce stigma and 
exclusion.  
 
Nutrition, treatment of opportunistic infections and basic palliative care methods extend 
quality and length of life. Antiretroviral drugs go a step further and, in most cases, achieve 
substantial increases in longevity and allow people to lead near normal lives. Nutrition, good 




Antiretroviral drug treatment (sometimes referred to as therapy) uses a combination of drugs 
to inhibit the replication of HIV and boosts the patient’s immune system. Antiretroviral 
treatment does not cure the condition, but it does bring substantial clinical benefits to the 
patient. An antiretroviral drug regime involves taking three drugs twice a day, and once 
started it must be adhered to rigidly: non-adherence reduces the benefits and increases the 
likelihood of drug resistant virus strains developing. Furthermore, a degree of clinical 
sophistication is needed to determine the drug regime for each individual. Antiretroviral 
treatment is complex, and this section is only a brief overview, the Appendix explains it in 
more detail. 
 
Antiretroviral treatment is generally applied at Stage 4 of the disease’s progression, the final 
stage of HIV/AIDS when a person’s ‘CD4’ count drops to below 200 (although it can drop to 
this level in earlier stages). At this stage, substantial increases in ‘viral load’ (the presence of 
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the virus in the blood) are usually observed, which also increases infectivity. Some 
practitioners start treatment earlier than Stage 4 to avoid problems associated with 
tuberculosis.  
 
Antiretroviral drugs have been described as having a “Lazarus effect” in bringing AIDS 
sufferers back to life, although some patients develop resistance to the drugs and others 
(about 6%) have such extreme side effects that the regime is suspended. Over the last six 
years, however, the introduction of antiretrovirals in Europe and the US has helped cut AIDS 
deaths by over 70%. In Brazil, AIDS mortality fell by 51% between 1996 and 1999, when 
antiretroviral treatment became universal. The development of resistant strains, however, is 
gradually reducing the effectiveness of antiretroviral drug programmes in some countries. 
The problem of ‘treatment anarchy’ leading to the development of resistant strains 
emphasises the need for coherence and co-operation. Private providers of antiretroviral 
drugs using incorrect protocols are a particular risk. In Central Africa the extent of resistant 
strains is not yet known, and whether indeed strains will emerge under treatment 
programmes. 
 
A big issue relating to antiretroviral drugs is their cost, which used to be prohibitive, but 
fortunately now is falling. The cheapest brand-name drugs cost $562 per patient per annum 
in the developing world. In the UK the price is much higher. However, generic drugs, 
manufactured in countries such as Brazil and India, are available to the developing world at 
much cheaper prices. The Clinton Foundation's HIV/AIDS Initiative secured a deal in 2003 
with generic drug makers Ranbaxy Laboratories, Cipla, Matrix Laboratories, Hetero Drugs 
and Aspen Pharmacare to reduce the cost of commonly used three-drug antiretroviral 
regimens to $139 per patient per annum. In April 2004 the Clinton Foundation brokered a 
deal between UNICEF, the World Bank and the Global Fund to Fight AIDS, Tuberculosis 
and Malaria to extend the scheme to more than 100 developing countries.73 
 
In practice, export costs tend to push the prices up. In addition, the drugs are mainly only 
available to purchasers of scale, governments for instance, at these prices. Smaller 
antiretroviral deliverers cannot access these prices. It is also important to include the price of 
laboratory testing and medical infrastructure when considering the cost of antiretroviral drug 
delivery. Some developing countries, such as Kenya (who have licensed production from 
GlaxoSmithKline), are starting to develop their own generic drug manufacturing capacity 
under licence, which would drive prices down further (from $552 per patient per annum to 
$396) and benefit the local economy.74 If, as planned, the government treats 180,000 
patients, this would save Kenya $28 million. 
 
Box 5: TRIPS and generic drugs75  76 
 
The rules governing pharmaceutical patent protection are enshrined in the Trade-
Related Aspects of Intellectual Property Rights Agreement (TRIPS) of the World 
Trade Organisation (WTO). It attempts to safeguard access to medicines in poor 
countries in the face of patent protection. It allows for developing countries to 
adopt compulsory licensing for the production or importation of generic medicines 
without the consent of the patent holder, in order to protect public health.  
 
This agreement was reached after much political wrangling at the WTO 
Ministerial Conference in Doha in November 2001, followed by further 
negotiations up to August 2003 when the conditions, in particular allowance for 
importation of generic drugs by countries who had no production capacity, were 
finally announced. Some of the language in the agreement is open to 
interpretation, and the implementation of the agreement does not always achieve 
its goals. 77   
 
In particular, TRIPS and the spirit of the agreement can be overridden by Free 
Trade Agreements between countries. The problem here is that the poorer 
countries who are supposed to benefit from the TRIPS arrangements find 
themselves in weak negotiating positions with wealthy countries which have 
strong pharmaceutical industry lobbies. There have been a number of examples 
of restrictions being negotiated between countries, such as the US, with various 
African, Central American and East Asian countries which are inconsistent with 
TRIPS.  
 
Manufacturers of generic drugs in countries such as India cannot automatically 
export their products to poor countries and must wait to be asked. Currently India 
is not part of TRIPS (it passed a law in the 1970s exempting it from international 
patent law) but when it accedes in 2005, Indian drugs will be much less available.  
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One figure often quoted is that the total cost of antiretroviral treatment is over $1,000 per 
patient per annum.78 This includes drugs, medical infrastructure and laboratory testing. In 
countries such as South Africa where health infrastructures are already developed, actual 
experience is cheaper ($55079 per patient per annum), but given the requirement to improve 
many health infrastructures, $1,000 per annum seems realistic.  
 
The net cost to society is significantly less than this, because people receiving antiretroviral 
drugs will make less use of hospitals than untreated AIDS patients. Brazil found that it saved 
around $850 in hospital costs per patient per annum during the first four years of its 
universal antiretroviral drug programme. 80   
 
The impact of antiretroviral drugs on a family is transformational. Children are not orphaned 
and are relieved of the burden of caring for their parent, allowing them to attend school 
(antiretroviral drug provision to one mother of four not only impacts her life, but four others 
as well). Mothers do not spend their days having to care for sick children and can work 
instead.  Partners are less likely to infect one another with variant HIV strains. 
 
Similarly, the impact of an antiretroviral drug programme on a particular community is 
substantial, albeit at considerable cost. Communities are more likely to participate in VCT 
programmes if treatment is available; education and prevention opportunities are increased. 
Confidence of communities is improved and the future risk of delinquency among youth is 
greatly reduced. Therefore the long-term economic benefits are considerable. Antiretroviral 
treatment also reduces the viral load of patients, thereby decreasing infectivity, which is an 
additional benefit.  
 
On the negative side, antiretroviral drugs have side effects such as vomiting, rashes, 
increased risk of cardiovascular disease, headaches and insomnia, sometimes of such 
severity that people drop out of the programmes. Good nutrition reduces the likelihood of 
poor adherence due to nausea and poor drug absorption.  
 
The provision of antiretroviral drugs raises some practical considerations: 
 
• Patient selection: Who gets priority when resources are finite? Might one create 
tensions within communities if some patients are treated and others not? Why 
should the sickest be favoured over healthier people? If one’s objective is to delay 
or prevent orphaning, then mothers may be favoured over other members of 
society, possibly leading to unforeseen social consequences. 
• Nutrition: Reasonable nutrition levels are a crucial component of the antiretroviral 
drug regime and access to income-generating activities (sometimes part of a 
programme) is helpful in this regard. 
• Adherence: This is essential for the success of antiretroviral treatment and there 
are several methodologies to promote good adherence levels, for instance the use 
of lay counsellors/patient advocates. 
• Counselling and support: This is essential to manage patient expectations and to 
promote adherence to the drug regime and responsible behaviour with sexual 
partners. 
• Support groups: These encourage adherence and help patients and families 
avoid stigmatisation.81  
• Clinical supervision: The administration of treatment is extremely labour-intensive 
during the initial months and the training of doctors and nurses to administer the 
programme is crucial. Primary health clinics and even tertiary hospitals show a poor 
record of administration of antibiotics to TB patients even in South Africa – this 
demonstrates how even a well-developed medical infrastructure has capacity 
limitations, so enormous capacity building would be required should the 
government roll out antiretroviral drugs.  
• Access to laboratory testing: This is necessary to keep track of progress. 
• Treatment of opportunistic infections: Access to ordinary medicines for 
infections and ailments, together with timely delivery of antiretroviral drugs to 
outlets is essential. Again, primary health clinics are frequently under-stocked with 
basic medicines.  
 
There is insufficient infrastructure in many countries to introduce widespread antiretroviral 
drugs responsibly and effectively at the current time. In well-managed programmes the 
adherence of patients is extremely encouraging. However, the medical profession as a 
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whole in Central Africa is not experienced in antiretroviral provision and unless this capacity 
is developed, it is difficult to foresee how patients will be able to adhere to the most 
appropriate regimes. The laboratory testing of patient bloods, which is a necessary part of a 
treatment programme, is not available in all parts of the country. On the other hand, once 
capacity and programmes are developed, the clinician’s life may be simplified because there 
is less need to treat a range of complex opportunistic infections. 
 
In some respects the epidemic represents an opportunity to develop health systems, 
however, the previous experience of some practitioners in other public health crises suggest 
that this may be a mirage. 82 
 
Box 6: An assessment of Tanzania’s infrastructure83 
  
The delivery of medical care of any description is a key issue, and Tanzania is an 
interesting case study.  
 
In a thinly-spread population of 34 million people growing at around 2% per 
annum (despite the HIV/AIDS epidemic), the availability of healthcare 
professionals is dropping alarmingly. There are currently around 160 “health 
professionals” per 100,000 of population, but over 30% of these are “attendants” 
with little direct medical impact. The absolute number of health professionals has 
dropped in the last decade, due largely to an employment freeze imposed by the 
IMF and World Bank in the nineties, and they are also ageing, which will lead to 
future personnel gaps. 
 
At current levels there is high availability of unskilled workers in the health sector, 
not all of whom are useful. Doctors, on the other hand, are urgently needed: only 
480 exist, but over 4,000 are required. With only 2.5 doctors per 100,000 of 
population, the delivery of healthcare is precarious. At present there are nearly 
enough nurses available, but by 2015 the study predicts that there will be a 
deficit of nursing resources of over 60%. 
 
This is hardly surprising in a country where per capital expenditure on healthcare 
is $6-7 per annum, and highlights a problem experienced by many resource poor 
countries. 
 
There is currently an urgent need for seed funding to develop infrastructure and a training 
platform in anticipation of future international funding. Medical NGOs therefore play a vital 
role in: 
 
• Developing models and evidence-based protocols (such as “DART” described 
below), which could realistically be rolled out to wider audiences. 
• Building capacity within government health systems to cope with antiretroviral 
drugs and related health issues, particularly in the rapid training of medical and 
related personnel in antiretroviral therapy. 
• Building capacity within health systems to cope with other health issues so that 
these are not ignored while all efforts are concentrated on HIV/AIDS. 
• Offering stopgap services while national governments develop operational plans 
and mobilise funding, thereby saving lives while policy is debated and programmes 
are developed. 
• Documentation of successful programmes and dissemination of findings. 
 
Private funders face a dilemma over the longevity of antiretroviral drug provision. While 
medically possible, it is ethically questionable to cease treatment of patients with 
antiretroviral drugs once started (apart from treatment in connection with PMTCT efforts). It 
is not yet clear whether stopping treatment makes it more likely for drug resistant HIV strains 
to develop, medical opinion appears divided. Programmes may be started in expectation 
that more substantial funders will step in at a later date, but if this does not occur, private 
funders will have to face the possibility of continued funding or cessation of programmes. 
The risk of drug cessation is a sensitive issue to people who are HIV positive, and in some 
places there is scepticism over the sustainability of funding for treatment. 
 
Considerable uncertainty exists about the impact of antiretroviral treatment on sexual 
behaviour and transmission. On the one hand, there is some evidence from the US and 
Europe that patients receiving antiretroviral treatment become more sexually active, 
engaging in unprotected sex, thereby increasing the likelihood of transmission. On the other 
Capacity building is 
essential in order to 
increase countries’ 




Funders face a 











funders can “pump 
prime” provision but 
resources will be 
required to take up 
the costs in the long 
term. 
 NPC HIV/AIDS - global context  February 2005 29 
hand, evidence to the contrary exists and, furthermore, the viral load of someone who is 
receiving antiretroviral drugs declines, making them less infectious to any sexual partners. 84  
  
Development of antiretroviral therapy (DART) 
 
The delivery of antiretroviral drugs, even with lower drug prices, is still expensive and it is 
useful to look at ways to drive down costs. Practitioners traditionally monitored patient 
progress by regularly monitoring CD4 counts and viral loads, which are costly procedures – 
particularly the latter. Laboratory costs are an area that the Medical Research Council is 
tackling through DART, with support from DfID and the Rockefeller Foundation. In particular, 
they are running trials in Uganda and Zimbabwe exploring the use of clinical monitoring only 
versus laboratory monitoring, the idea being that if one can reduce the need for laboratory 
testing, then a great deal of money can be saved. This would also be very helpful in areas 
where laboratory testing is not easily available – a big issue in Central Africa. NPC estimates 
that it costs between $100-150 per patient per annum for full laboratory testing.85 As viral 
load testing is more costly than CD4 counting it may also be interesting to explore ways of 
reducing the amount of viral load testing.86 
 
MRC is also trialling comparisons between planned treatment interruptions (which would 
reduce the need for drugs on a continuous basis) and continuous treatment in order to drive 
down drug costs and mitigate patient side effects. They are trialling this in both adult and 
paediatric treatment. 
 
Antiretroviral drugs to children 
 
This presents a terrible humanitarian dilemma. In a resource-poor environment where 
treatment is rationed, very young children are neither carers nor bread-winners. The 
preservation of children at the expense of adults can ironically increase the numbers of 
orphans by keeping children alive to become orphans.  
 
In practice, antiretroviral drugs programmes increasingly favour treating whole families 
where possible. This reduces tensions within families: mothers are unlikely to accept their 
own treatment while watching the demise of a child, and a treated child is less of a burden 




On balance, the benefits of providing antiretroviral drugs largely outweigh the costs and 
risks. There needs to be sufficient infrastructure for delivery in place – clinical supervision, 
patient support, counselling and education – to make an antiretroviral treatment project work 
well. To enjoy economies of scale and to benefit a community, rather than isolated 
individuals (envy can be disruptive if only a few are treated), antiretroviral drug programmes 
have to be of a reasonable size. 
 
General care and support 
As explained earlier, HIV patients are not generally suitable for antiretroviral treatment until 
the disease progresses to AIDS. In any case, antiretroviral treatment may not be available or 
clinically appropriate. Good prevention and management of opportunistic infections, nutrition 
and “healthy living” can delay the onset of late stage AIDS. Such support should be viewed 
as an integral part of treating any group of patients and has added cost benefit.  
 
Furthermore, when there are insufficient resources to pay for any antiretroviral treatment, or 
when a person has a drug resistant HIV strain or suffers extreme side effects from the drugs, 
it is important to provide them with a dignified way of spending their final years. Residential 
hospices are too expensive to be a widespread solution and are not always suited to an 
African lifestyle. Community-based home care programmes can, however, be very effective 
in improving the quality of life for AIDS sufferers and their families and these programmes 
sometimes even extend life.  
 
Nutrition and living conditions  
 
Although it appears that there are no clinical studies comparing malnourished control groups 
with well-nourished patients, medical practitioners agree that nutrition is a crucial component 
in the treatment of AIDS.87 Patients require increased levels of protein, vitamins, minerals 
and calories. Malnutrition is often a key problem for patients resulting in a vicious downward 
spiral of lower energy, increased sickness and reduced ability to generate income, thereby 
further reducing nutritional intake. Projects attempting to encourage and improve cultivation 
of crops in rural areas are helpful in this regard. The cost of good basic nutrition, which can 
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have an enormous impact and boost a patient’s energy level (for work or childcare), health 
and sense of well-being, is around $90-100 per annum in South Africa.  
 
Access to clean water is an issue for people with HIV and AIDS, whether on antiretroviral 
treatment or not. There is no easy answer to this given that the provision of clean water, 
particularly in rural areas, is expensive. Care programmes should include education on 
water hygiene. 
 
General medical and palliative care* 
 
The prevention and treatment of opportunistic infections, such as thrush (oral as well as 
genital), is crucial. For example, patients suffering from oral thrush are often unable to eat.88 
TB and forms of the herpes virus also commonly afflict AIDS patients in debilitating and 
painful ways. Diarrhoea is a regular problem, and untreated diarrhoeal infections further 
exacerbate nutrition difficulties and accelerate the progress of AIDS.  
 
The challenge in many resource-poor environments is the lack of qualified medical 
practitioners and health workers. HIV/AIDS is not the only disease affecting the poor, and 
it is important that the general health of all people in a community is maintained. There are 
concerns that if too much attention is placed on HIV/AIDS, vital resources will be diverted 
away from other medical conditions.  
 
Palliative care is important because it is not only humane, but gives patients dignity and 
provides families with support and sense of value: its benefits are discussed in more detail 
below. However not all countries have developed models as good as the integrated 
community based home care one developed in South Africa. Some countries may have 
slightly different systems, which afford some degree of care, but many countries have no 
such care models. 
 
Integrated community based home care (ICHC) 
 
In South Africa, hospices have developed an integrated community based home care model.  
This links hospices, primary health care clinics and hospitals as well as caregivers in 
developing a care plan for patients, and training health professionals and volunteers. 
Caregivers work in teams with nursing and medical supervision, social workers and 
bereavement counsellors who then go into the community to train and support carers of 
AIDS patients (generally family members) in the home in basic nursing skills.  
 
This model of care also provides psycho-social and spiritual support to patients and the 
bereaved. There is anecdotal evidence that the psychological well-being of patients has a 
bearing on longevity and quality of life, helping to combat the isolation and depression 
frequently associated with AIDS. Such a measure also reduces the trauma for children 
watching the passage of life of a loved one through sickness to death, and reduces the 
feelings of helplessness among family members.  
 
Bereavement support is part of this process. Interventions are crucial if the child is to recover 
sufficiently to control its own life (for example, saying no to sex), make the best of education, 
and eventually become an independent adult. Memory Boxes or Memory Books are now 
being used to help this process (see box 7). 
 
Box 7: Memory boxes, bags and books 
A Memory Box† is a measure that has been successfully deployed in South 
Africa and Uganda. It is created for the child by its parents or by the child itself 
(lovingly and beautifully hand-decorated) and might contain documentation: birth 
certificate and ID documents, a family album containing stories, photographs and 
drawings, a family tree to help identify relatives for future tracing, a will including 
intentions for the placement of child with trusted relatives and details regarding 
inheritance of possessions, letters to the child and other treasured objects. 
 
A Memory Box project provides a conduit through which people can confront 
AIDS and its implications. It is a useful tool to place at the heart of the grieving 
process.  
                                                           
* “Palliative care is the active total care of patients whose disease is not responsive to 
curative treatment. Control of pain, of other symptoms, and of psychological, social and 
spiritual problems is paramount.”  WHO 1990 
 
† A Memory Box can sometimes be a Memory Bag or Memory Book with a pocket in the book sleeve 
Good nutrition 
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 NPC HIV/AIDS - global context  February 2005 31 
The advantage of the ICHC model is that it uses caregivers who are part of the community 
and know the families concerned and are always on the lookout for new cases. It also 
provides an entrée to the family when providing other services such as bereavement 
counselling, help with placement planning of children, and placement once the children are 
orphaned. Caregivers report frequent opportunities to improve HIV/AIDS education in the 
immediate family and community. Funders should support the development of home based 




The effect of psychological well-being on life expectancy should not be underestimated. 
Interviews with HIV positive mothers in support groups emphasise the importance of mutual 
support and contact – without the support groups they would have lost the will to live89. 
Support groups are less expensive than one-to-one counselling, and can reduce and even 
replace the need for it. They are easy to establish and can be combined with self-sufficiency 
projects, eg, income generation or gardening.  
 
There is enormous stigma associated with having HIV/AIDS. Even in a society where death 
is commonplace from other causes, few people want to associate with AIDS patients; the 
community at large views investing social or other energy in someone who is dying as 
wasted effort. People may view an HIV positive woman, for instance, as unclean, potentially 
polluting the men in her community. Support groups for people with AIDS, coupled with 
community education, can help to overcome stigma within communities and reduce isolation 
for AIDS sufferers.  
 
Support groups are also important in helping to prevent HIV positive mothers abandoning 




People affected by HIV/AIDS 
“Orphanhood is a process that starts long before the death of the child’s caregiver.” 90 
 
The consequences of the disease badly affect many people, especially children, within the 
circle of a person with HIV. Children are probably worst hit, but also affected are the parents 
of sufferers, siblings, relatives, and the wider community who are left to pick up the pieces 
left behind by bereavement and trauma. It is hoped that treatment initiatives in some areas 
will stem the flow of bereavements, but as so small a percentage will have access, those 
affected will still need support. Indeed, it is the view of some practitioners that given the 
emphasis on prevention and treatment, orphans and vulnerable children and their 
families are not receiving the resources they need. Philanthropists can be particularly 
helpful in this area. This section deals with the numerous measures trying to address the 
issue. 
 
For a child, the preferable outcomes after bereavement, in order, are:  
 
(1) Remaining within the family in the community in which he or she has been 
brought up. Assuming there is no abuse or neglect within the family; this results in 
the least possible trauma for children (even in a child headed household). Transfer 
to an unknown extended family in an unfamiliar place may not be particularly 
desirable and it is difficult to monitor potential abuse or neglect. Children generally 
fare better if kept with their siblings. 
(2) Remaining within the community through foster care or placement in small family 
homes so that children remain close to their roots. Again, trauma may be reduced if 
a child remains in familiar surroundings and this also encourages the community to 
participate in the response. 
(3) Fostering or placement with a good family in a new community. 
(4) Institutionalisation. A temporary or permanent stay in an orphanage may be 
unavoidable (eg, for abandoned babies, street children etc.). Institutionalisation is 
preferable to a life on the street, but is not ideal for child development. 
Unfortunately some children slip through the net and end up on the street, in which case 
support for them is helpful, but difficult to provide. 
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Aside from (4), all of the above are relatively low cost, although in countries where there are 
no social services, it will be the families and communities who foster the children that will 
bear the cost of looking after them. This presents enormous challenges. 
 
Institutionalisation in orphanages is a less positive outcome than other solutions and is, in 
any case, considerably more expensive than other measures. Day care centres, where they 
exist, are helpful adjuncts to initiatives, providing respite for the carers and places of safety, 
development and nutrition for the children. 
 
The future for children who do not receive any help is extremely bleak. It is clear that 
orphans left to their own devices do extremely badly and one can assume negative 
outcomes (including high risk of eventual HIV status) for unattended orphans. If large 
numbers lack benefits, then the outlook for the future social development of communities is 
grim: unattended children will quickly grow into disaffected adolescents and young adults 
who turn to crime and delinquency as a way of life.  
 
There is a growing consensus that in order to serve children best, initiatives need to target 
the family caring for the child, rather than singling out the orphan for special attention.  
 
Orphan placement, foster care and child-headed households 
 
Proper placement is crucial to the emotional development of children. In some cases it is 
possible to place a child with a member of an extended family or neighbour. However, there 
are cases where no such adult exists: the romantic ideal of the extended family in some 
areas may be a myth, particularly if there have been population movements or there is high 
HIV/AIDS prevalence. Even if a grandmother is able to support children immediately after 
they are bereaved, she herself may be old or sick and lose the ability to care. Support for 
child-headed households, therefore, may be a reasonable alternative, particularly if the 
help is both material and emotional and includes an element of mentoring. The benefit of this 
is that the children are more likely to retain their family assets, and sibling groups are not 
broken up.  
 
Foster care schemes to place orphans with women or couples whose children are grown up 
or who are unable to conceive have been developed successfully in some areas. Between 
four and six children may be placed, although there are schemes that place more with 
families. Small family homes of larger numbers of children are also seen as a solution in the 
absence of better alternatives. 
 
HIV positive children are more likely to be abandoned than their negative counterparts 
because mothers feel unable to cope with the prospect of caring for a sick child. These 
children, in turn, are more difficult to foster.  
 
Box 8: Role of faith based organisations (FBOs) in providing care across 
the spectrum – report by UNICEF 
UNICEF researched the activities of 690 FBOs in six countries and found that 
they provided a broad range of community-based services, particularly material 
support to orphans and care for the sick. It found them to be adaptable and 
responsive. Although individually small, the cumulative impact of thousands of 
initiatives is considerable. The researchers also found that FBOs were well-
organised: those lacking transparency and organisation were not supported by 
local communities. FBOs are able to tap into volunteer resources, although 
financial resources in such poor communities are often limited.  
 
 
Material and practical support – nutrition, education and registration 
 
Money is often short when people are sick (they are unable to earn a living and at the same 
time require expensive medication) and in the period after their death. To add to the family’s 
burden, funeral costs are high. Consequently, in families with patients or recently dead 
carers, children have shocking levels of nutrition and development. Food parcels are often 
the only way to adequately nourish children.  
 
Maintaining a child’s education is also a challenge. Two types are relevant: minding very 
young children and preparing them for school, and education from primary school onwards 
where uniforms and school fees are the concerns. Families who have lost the main 
breadwinner struggle to keep children in school. Older children leave school to earn income 
to support other family members. Financial support and flexible learning opportunities are 
required here.  
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There are large numbers of children who have no official records, and this has implications 
for their welfare. This puts large numbers at risk of abuse and trafficking, the worry being 
that they won’t be missed if they disappear. In countries such as South Africa, registration of 
birth and death certificates has the added benefit of qualifying children for grants from the 
social services – but not all countries provide this.  
 
Counselling for bereaved, care of carers  
 
Bereavement is hard to bear, particularly after witnessing a long illness. It can sometimes be 
difficult to reach children who have suffered so much and lost their childhood. Self-esteem 
will be extremely low, and in the worst cases neighbours or relatives will abuse vulnerable 
children.  
 
It is difficult to gauge how these children will mature. Many people in the field fear that they 
may become alienated and excluded as a result of their experiences. Some children will 
express this by withdrawing, others by becoming angry and aggressive. Counselling can 
help children adjust to such extreme circumstances, although it is difficult to quantify its 
success. Children’s support groups in South Africa have been found to be an effective (and 
cheap) counselling tool. 
 
Institutions and shelters 
 
The problem of orphans is so large that in some communities the ideal models (placement 
with families) may not be achievable. If a child has nobody to look after them, the only option 
might be to place the child in institutional care, preferably within local communities. HIV 
positive children are particularly at risk of abandonment and less likely to attract fostering or 
adoption. Children who end up living on the street harden quickly and a street child requires 
intensive rehabilitation. Street children often come from disintegrating families split by 
poverty, which is why initiatives keeping the remnants of the family together are so 
important. Good shelters will take the trouble to trace communities and families as quickly as 
possible to try and place children back at home, but often there is nobody for them to go to. 
 
Inheritance – widows and orphans 
 
There is a risk that unscrupulous relatives will snatch property away from children who 
inherit it – the protection of property inheritance for the children, is vitally important. Widows 
are also at risk: in many societies, men retain the property, so if the man dies, the wife is left 
destitute. In addition, the practice of inheriting a dead brother’s widow can introduce infection 
to a new family – although it might ensure her support in the short term.  
 
Sustainability of initiatives 
 
When helping orphans and vulnerable children it is important not to discriminate in favour of 
those orphaned by AIDS over those orphaned for other reasons. Such discrimination divides 
communities and is inequitable. 
 
If a support group includes an income generating scheme (that is genuinely profitable) then 
so much the better. Self-esteem, independence and motivation are useful outcomes of such 
schemes as well as the importance of livelihoods in providing nutrition and access to 
transport. As poverty is linked to both the spread of AIDS and the problems of affected 
people, poverty alleviation is important. Many hospices, NGOs, and community based 
organisations have an income generation programme in their portfolio of activities, although 
not all schemes are genuinely profitable and so need to be carefully assessed.  
 
The production of cheap food for both nutrition and income is important to many families but 
not all have the know-how or means to cultivate food.  
 
On a more macro level, it is clear that the more a community can marshal its own resources 
to cope with the crisis, the better. Responses that include large numbers of volunteers and 
involve community based and grass roots organisations not only provide better cost per user 
results, but are also more likely to survive and take hold. Similarly, it is important that 
external support does not undermine community initiative and motivation and is based on 
community preferences. 
 
The role of people with AIDS in all initiatives is important. As activists, educators, advocates, 
and advisers, people with AIDS can be powerful in driving change. NGOs also report that 
people with AIDS can encourage peers to change behaviour.  
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Regional initiatives 
HIV/AIDS spreads across borders, particularly when communities are displaced through 
conflict. The Great Lakes Initiative Against AIDS (GLIA) has been formed to reduce HIV 
infections and to mitigate the socio-economic impact of the epidemic in the Great Lakes 
Region by developing regional collaboration and implementing initiatives that can add value 
to the efforts of each individual country. 
 
There are six member countries – Burundi, DRC, Kenya, Rwanda, Tanzania and Uganda. 
GLIA is currently in discussions with MAP for funding and a full range of implementing 
partners (UNAIDS, UNHCR, IRC) to develop surveillance and sentinel sites (both 
behavioural and, where possible, biological) in nine to ten refugee camps scattered around 
the region. Although there are VCT services in some of the refugee camps, the implications 
of the data are not being considered at a regional level and the policy implications not yet 
being fully explored. 
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Section 3: Outcomes from responses 
 
The resources available to tackle HIV/AIDS fall far short of the need. It is therefore 
desirable that private giving is targeted at initiatives that have demonstrably effective 
outcomes. It is difficult to spend money without doing some good. However, unlike 
governments, which may choose initiatives that are politically uncontroversial and 
popular, donors have the freedom to focus on the measures that are most effective. 
 
Introduction 
The outcomes available from the different responses discussed earlier are: 
 
• Preventing HIV from spreading to adults or children; 
• Treating those with HIV/AIDS to extend their life; 
• Caring for those dying of AIDS to improve the quality of their final years and 
support families trying to cope 
• Protecting orphans and children who are at risk of losing their caregiver to AIDS.  
 
Some strategies will have outcomes fitting a number of these categories, some will fit just 
one. When assessing outcomes it is often useful to distinguish between the cost per user 
and the cost per successful user. All charitable activities are targeted towards achieving 
positive outcomes. However, some are more successful than others. An initiative that 
succeeds in only 10% of cases has a cost per successful user ten times higher than its cost 
per user. As methods vary in their success rates, these two measures of unit cost are often 
considerably different and both are of interest to donors.  
 
The effectiveness of each response can be assessed on three levels: 
 
(1) Raw output, eg, the number of condoms distributed by a safe sex project or the 
number of patients receiving antiretroviral drugs. 
(2) Direct outcomes, eg, the increase in condom use or the number of patients whose 
immune systems recover as a result of the drugs. 
(3) Quantified impact, eg, the number of HIV infections prevented, the years of life 
gained by patients, adjusted for quality, or the economic benefit to society. 
 
The output (1) is by far the easiest of these to measure, and is therefore the level of 
assessment that charities most frequently quote, but is not very useful in making 
comparisons. Considerable information gathering is needed to measure the outcomes (2) 
reliably, but these figures are much more useful in assessing the effectiveness of measures 
and allocating resources. Comparable data on the impact (3) is the most useful measure of 
effectiveness and enables funders to make clearly informed choices between different kinds 
of measure. Unfortunately, complex calculations, involving assumptions on issues such as 
the epidemiological spread of HIV and the expected life span of a person without HIV, are 
needed to move from the direct outcome data to a good estimate of impact. 
 
Ideally, good level (3) information would be available for all the different measures. It could 
then be compared to the cost of each measure to estimate cost-effectiveness. This would 
enable a comparison of the cost of funding one sort of intervention versus another. Where 
possible this section quotes level (3) cost-effectiveness data; although this data often comes 
from other African countries, their circumstances are sufficiently similar to Central Africa to 
be relevant. Unfortunately the information available is not as broad or reliable as one might 
hope. 
 
Measuring outcomes is an activity fraught with problems. There are considerable difficulties 
both in defining success and in costing projects aimed at success. There is also the problem 
of longevity of success in projects trying to achieve long term societal changes, which are 
not measurable within a two-three year time scale. The actual data available is poor: 91 
 
• Costing methodology varies widely and may not be comparable 
• Randomised control trials (RCTs) are scarce 
• Some of the studies focus heavily on DALYs or QALYs.*  
                                                           
* DALYs = Disability adjusted life years; QALYs = Quality adjusted life years. The problem with using 
such measurements ( how many years of a person’s life do you buy) is that it misses many of the social 
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Nevertheless, grappling with these difficulties is a useful exercise, because some 
understanding of what constitutes success and the cost effectiveness of the initiatives is 
better than none. Because of the difficulties, the discussion that follows should not be 
regarded as conclusive, but is aimed at helping donors interested in directing funding to 




Table 2 gives a summary of costs of the various initiatives. Quantitative statistics should not 
be read in isolation however, and the efficacy of the NGO providing the initiative (including 
characteristics such as local participation, capacity building, and social impact) should be 
considered in tandem. 
 










Cost per pip, 
US$ 
      
Prevention      
Education  and 
awareness 9 8 9 16-32 – 
VCT 9 8 8 4-39 264-367 
Social marketing 
condoms    negligible 24 
Condoms/ STI 
treatment for sex 
workers 
9 8 8 6 19-30 
Treatment of STIs 9 8 8 2.50-16 11-260 
      
PMTCT - Nevirapine 9 8 8 4-8 27 
PMTCT - HAART 9 8 8 250 862 
Blood security     52 
      
Treatment and care     Cost over life 
Antiretroviral drugs ? 99 9 1,000 pa c10,000 
Antiretroviral drugs – 
impact on children 8 8 9 
200 pa  
per child 2,000 
Community based 
care ? 9 9 
125-430 
pa – 
      
Services to children      
Fostering 8 9 9 390 – 
Education 8 9 9 71-480 pa  
Nutrition 8 9 8 103 pa – 
Combined family 
support Rwanda - ie, 
four children 
? 9 9 1,780 pa per family  
445 per 
child 
      
 
Table 2 includes estimates, where sufficient data are available, of the cost of each 
intervention per user and, when it is measurably different, the cost per successful 
intervention. These outcomes highlight difficult choices for donors in terms of resource 
allocation. Often the choice is between helping large numbers of people (eg, registration, 
palliative care) versus helping fewer numbers of people (eg, antiretroviral drugs – although 
with antiretroviral drugs there is a ripple effect upon the family) but in a more profound way. 
The choices are also influenced by what programmes are available, or feasible to develop in 
the immediate future, and how much money a grant-maker or donor is willing to spend.  
                                                                                                                                                       
nuances around who it is you are saving. For instance, by saving the life of a 30-year-old woman, you 
may achieve relatively few DALYs, but the effect on her children, which escapes the DALY calculation, 
is invaluable.  
 
Donors can either 
help a large number 
of people in small 
but effective ways, 
or they can help 
smaller numbers of 
people and have a 
more profound 
effect on individual 
lives.  
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Conclusion  
 
There is an urgent need for the developed world to take notice of the HIV pandemic as there 
are far reaching consequences of allowing it to continue unchecked. The challenge of 
addressing the epidemic is not only financial: there are logistical, social, and managerial 
hurdles which can inhibit responses to the problem. However there are opportunities for 
donors to help organisations that are attempting to overcome the challenges, not only by 
circumventing the hurdles but also addressing the hurdles themselves. 
 
Section 3 gave a broad overview of the various outcomes generated by specific activities. In 
reality, however, the funding options available in some very poor regions may be different to 
those identified here and may not be neatly packaged, but this is a useful tool to refer to as 
an approximation of the results of resource allocation. Activities are usually more effective 
when conducted simultaneously.  
 
NPC’s additional reports Out of the Shadows (Burundi, Democratic Republic of Congo, 
Rwanda), and Rhetoric to Action (South Africa) provide greater details on the specifics of 
these countries and make some funding recommendations.  
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